Combination of antibody-drug conjugates and immune checkpoint inhibitors
Patent Information
- Application Number
- JP2024130545
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-09-25
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2037-12-11
AI Technical Summary
【0036】 本発明により、特定の抗体-薬物コンジュゲートと免疫チェックポイント阻害剤が組み合わされて投与されることにより、抗腫瘍効果と安全性面に優れる医薬組成物及び治療方法を提供することができる。また、本発明により、特定の抗体-薬物コンジュゲートを含有することを特徴とする、腫瘍に対する免疫記憶形成を促進する作用により改善される疾患の治療用の医薬組成物及び治療方法を提供することができる。
Smart Images

Figure 2024156920000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a pharmaceutical composition and a treatment method, which are characterized in that a specific antibody-drug conjugate and an immune checkpoint inhibitor are administered in combination, as well as a pharmaceutical composition and a treatment method, which contain a specific antibody-drug conjugate and are used for treating diseases that are improved by the action of activating anti-tumor immunity. [Background technology]
[0002] Antibody-drug conjugates (ADCs), which combine a cytotoxic drug with an antibody that binds to an antigen expressed on the surface of cancer cells and can be internalized into the cells, are expected to be able to selectively deliver the drug to cancer cells, thereby accumulating the drug in the cancer cells and killing the cancer cells (Non-Patent Documents 1 to 5).
[0003] One type of antibody-drug conjugate known is one that contains an antibody and exatecan, a topoisomerase I inhibitor, as components (Patent Documents 1 to 7). Of these, anti-HER2 antibody-drug conjugates (Non-Patent Documents 6 and 7), which have particularly excellent antitumor effects and safety, are currently undergoing clinical trials.
[0004] Immune checkpoint inhibitors are drugs that inhibit the immunosuppressive system and activate antitumor immunity (Non-Patent Documents 8 to 10). Known immune checkpoint inhibitors include anti-PD-1 antibodies, such as Nivolumab (Patent Document 8) and Pembrolizumab (Patent Document 9), anti-PD-L1 antibodies, such as Atezolizumab (Patent Document 10), Durvalumab (Patent Document 11), and Avelumab (Patent Document 12), and anti-CTLA-4 antibodies, such as Ipilimumab (Patent Document 13), and Tremelimumab (Patent Document 14).
[0005] As an example of a case in which an antibody-drug conjugate and an immune checkpoint inhibitor have been administered in combination, there is a study on the combined use of trastuzumab emtansine (T-DM1) and an anti-CTLA-4 / PD-1 antibody (Non-Patent Document 11). [Prior art documents] [Patent documents]
[0006] [Patent Document 1] International Publication No. 2014 / 057687 [Patent Document 2] International Publication No. 2014 / 061277 [Patent Document 3] International Publication No. 2015 / 098099 [Patent Document 4] International Publication No. 2015 / 115091 [Patent Document 5] International Publication No. 2015 / 146132 [Patent Document 6] International Publication No. 2015 / 155976 [Patent Document 7] International Publication No. 2015 / 155998 [Patent Document 8] International Publication No. 2006 / 121168 [Patent Document 9] International Publication No. 2008 / 156712 [Patent Document 10] International Publication No. 2010 / 077634 [Patent Document 11] International Publication No. 2011 / 066389 [Patent Document 12] International Publication No. 2013 / 079174 [Patent Document 13] International Publication No. 2001 / 014424 [Patent Document 14] International Publication No. 2000 / 037504 [Non-patent literature]
[0007]
Non-licensed literature 1
Non-licensed Document 2
Non-licensed Document 4
Non-licensed Document 5
Non-licensed Document 6
Non-licensed Document 7
Non-licensed literature 9
Non-licensed literature 10
Non-licensed Document 11
[0008] An objective of the present invention is to provide a pharmaceutical composition and a treatment method that have excellent antitumor effects and safety by administering a combination of an antibody-drug conjugate and an immune checkpoint inhibitor.Another objective of the present invention is to provide a pharmaceutical composition and a treatment method that contain a specific antibody-drug conjugate and are used for treating a disease that is improved by the action of activating antitumor immunity. [Means for solving the problem]
[0009] The present inventors have found that the administration of a specific antibody-drug conjugate in combination with an immune checkpoint inhibitor exhibits an excellent antitumor effect, and have also found that the antibody-drug conjugate has the effect of activating antitumor immunity.
[0010] That is, the present invention provides [1] A pharmaceutical composition comprising an antibody-drug conjugate and an immune checkpoint inhibitor administered in combination, The antibody-drug conjugate has the formula
[0011] [ka]
[0012] (wherein A represents the binding site to the antibody) and an antibody via a thioether bond. [2] The pharmaceutical composition according to [1], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody. [3] The pharmaceutical composition described in [2], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody. [4] The pharmaceutical composition according to [2] or [3], wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2. [5] The pharmaceutical composition according to [2] or [3], wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2. [6] The pharmaceutical composition according to any one of [1] to [5], wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 2 to 8. [7] The pharmaceutical composition according to any one of [1] to [5], wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8. [8] The pharmaceutical composition according to any one of [1] to [5], wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7.5 to 8. [9] The pharmaceutical composition according to any one of [1] to [8], wherein the immune checkpoint inhibitor is an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.
[10] The pharmaceutical composition described in [9], wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.
[11] The pharmaceutical composition described in [9], wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody.
[12] The pharmaceutical composition described in [9], wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody.
[13] The pharmaceutical composition according to any one of [1] to
[12] , wherein the antibody-drug conjugate and the immune checkpoint inhibitor are contained as active ingredients in separate formulations and are administered simultaneously or at different times.
[14] The pharmaceutical composition according to any one of [1] to
[12] , characterized in that the antibody-drug conjugate and the immune checkpoint inhibitor are contained as active ingredients in a single formulation and administered.
[15] A pharmaceutical composition described in any one of [1] to
[14] for the treatment of cancer.
[16] The pharmaceutical composition according to
[15] , wherein the cancer is at least one selected from the group consisting of lung cancer, urothelial carcinoma, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
[17] The pharmaceutical composition described in
[16] , wherein the cancer is colorectal cancer.
[18] The pharmaceutical composition described in
[16] , wherein the cancer is breast cancer.
[19] The pharmaceutical composition according to any one of [1] to
[18] , wherein the antibody-drug conjugate has the effect of activating anti-tumor immunity.
[20] The antibody-drug conjugate is (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells The pharmaceutical composition according to any one of [1] to
[19] , having at least one effect selected from the group consisting of: [twenty one] The pharmaceutical composition according to any one of [1] to
[20] , wherein the antibody-drug conjugate has the effect of promoting immune memory formation against a tumor. [twenty two] The pharmaceutical composition described in
[21] , wherein the tumor expresses an antigen against which the antibody in the antibody-drug conjugate is directed. [twenty three] The pharmaceutical composition described in
[21] , wherein a portion of the tumor does not express an antigen against which the antibody in the antibody-drug conjugate is directed. [twenty four] The antibody-drug conjugate is (1) Promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; The pharmaceutical composition according to any one of [1] to
[23] , having at least one effect selected from the group consisting of: [twenty five] The pharmaceutical composition according to any one of [1] to
[24] , characterized in that the antibody-drug conjugate exhibits a stronger antitumor effect by neutralizing an immunosuppressive signal generated by the antibody-drug conjugate promoting an increase in the expression level of PD-L1 on cancer cells, with the immune checkpoint inhibitor.
[26] formula
[0013] [ka]
[0014] (wherein A represents the binding site to the antibody) and an antibody via a thioether bond, and the pharmaceutical composition is used for treating a disease that is improved by the activity of activating anti-tumor immunity.
[27] The antibody-drug conjugate is (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells The pharmaceutical composition described in
[26] , having at least one effect selected from the group consisting of:
[28] The pharmaceutical composition according to
[26] or
[27] , wherein the antibody-drug conjugate has the effect of promoting immune memory formation against a tumor.
[29] The pharmaceutical composition of claim
[28] , wherein the tumor expresses an antigen against which the antibody in the antibody-drug conjugate is directed.
[30] The pharmaceutical composition described in
[28] , wherein a portion of the tumor does not express an antigen against which the antibody in the antibody-drug conjugate is directed.
[31] The antibody-drug conjugate is (1) Promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; The pharmaceutical composition according to any one of
[26] to
[30] , having at least one effect selected from the group consisting of:
[32] The pharmaceutical composition according to any one of
[26] to
[31] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody.
[33] The pharmaceutical composition according to
[32] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[34] The pharmaceutical composition according to
[32] or
[33] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.
[35] The pharmaceutical composition according to
[32] or
[33] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.
[36] The pharmaceutical composition according to any one of
[26] to
[35] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 2 to 8.
[37] The pharmaceutical composition according to any one of
[26] to
[35] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.
[38] The pharmaceutical composition according to any one of
[26] to
[35] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7.5 to 8.
[39] The pharmaceutical composition according to any one of
[26] to
[38] , wherein the disease is at least one selected from the group consisting of lung cancer, urothelial carcinoma, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
[40] The pharmaceutical composition described in
[39] , wherein the disease is colorectal cancer.
[41] The pharmaceutical composition described in
[39] , wherein the disease is breast cancer.
[42] formula
[0015] [ka]
[0016] A pharmaceutical composition for use in the treatment of a disease that is improved by the activity of activating anti-tumor immunity, comprising a compound represented by the formula (I):
[43] The compound is (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells The pharmaceutical composition according to
[42] , having at least one effect selected from the group consisting of:
[44] The pharmaceutical composition according to
[42] or
[43] , wherein the compound has the effect of promoting immune memory formation against a tumor.
[45] The compound is (1) Promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; The pharmaceutical composition according to any one of
[42] to
[44] , having at least one effect selected from the group consisting of:
[46] The pharmaceutical composition according to any one of
[42] to
[45] , wherein the disease is at least one selected from the group consisting of lung cancer, urothelial carcinoma, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
[47] A therapeutic method comprising administering an antibody-drug conjugate and an immune checkpoint inhibitor in combination, The antibody-drug conjugate has the formula
[0017] [ka]
[0018] (wherein A represents the binding site to the antibody) and an antibody-drug conjugate in which the drug linker represented by the formula:
[48] The treatment method described in
[47] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody.
[49] The treatment method described in
[48] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[50] The treatment method described in
[48] or
[49] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.
[51] The treatment method described in
[48] or
[49] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.
[52] The treatment method according to any one of
[47] to
[51] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 2 to 8.
[53] The treatment method according to any one of
[47] to
[51] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.
[54] The treatment method according to any one of
[47] to
[51] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7.5 to 8.
[55] The therapeutic method described in any one of
[47] to
[54] , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.
[56] The therapeutic method described in
[55] , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.
[57] The therapeutic method described in
[55] , wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody.
[58] The therapeutic method described in
[55] , wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody.
[59] The therapeutic method according to any one of
[47] to
[58] , wherein the antibody-drug conjugate and the immune checkpoint inhibitor are contained as active ingredients in separate formulations and administered simultaneously or at different times.
[60] The therapeutic method described in any one of
[47] to
[58] , characterized in that the antibody-drug conjugate and the immune checkpoint inhibitor are contained as active ingredients in a single formulation and administered.
[61] A therapeutic method described in any one of
[47] to
[60] for the treatment of cancer.
[62] The method for treating cancer according to
[61] , wherein the cancer is at least one selected from the group consisting of lung cancer, urothelial carcinoma, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
[63] The treatment method described in
[62] , wherein the cancer is colorectal cancer.
[64] The treatment method according to
[62] , wherein the cancer is breast cancer.
[65] The therapeutic method according to any one of
[47] to
[64] , wherein the antibody-drug conjugate has the effect of activating anti-tumor immunity.
[66] The antibody-drug conjugate is (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells The pharmaceutical composition according to any one of
[47] to
[65] , having at least one effect selected from the group consisting of:
[67] The therapeutic method according to any one of
[47] to
[66] , wherein the antibody-drug conjugate has the effect of promoting immune memory formation against a tumor.
[68] The treatment method described in
[67] , wherein the tumor expresses an antigen against which the antibody in the antibody-drug conjugate is directed.
[69] The treatment method described in
[67] , wherein a portion of the tumor does not express an antigen against which the antibody in the antibody-drug conjugate is directed.
[70] The antibody-drug conjugate is (1) Promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; The method for treatment according to any one of
[47] to
[69] , having at least one effect selected from the group consisting of:
[71] The therapeutic method according to any one of
[47] to
[70] , characterized in that the antibody-drug conjugate exhibits a stronger antitumor effect by canceling an immunosuppressive signal generated by the antibody-drug conjugate promoting an increase in the expression level of PD-L1 on cancer cells, using an immune checkpoint inhibitor.
[72] formula
[0019] [ka]
[0020] (wherein A represents the binding site to the antibody) and an antibody via a thioether bond, wherein the antibody-drug conjugate is administered to the subject.
[73] The antibody-drug conjugate is (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells The treatment method described in
[72] , which has at least one effect selected from the group consisting of:
[74] The therapeutic method according to
[72] or
[73] , wherein the antibody-drug conjugate has the effect of promoting immune memory formation against a tumor.
[75] The treatment method described in
[74] , wherein the tumor expresses an antigen against which the antibody in the antibody-drug conjugate is directed.
[76] The treatment method described in
[74] , wherein a portion of the tumor does not express an antigen against which the antibody in the antibody-drug conjugate is directed.
[77] The antibody-drug conjugate is (1) Promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; The method for treatment according to any one of
[72] to
[76] , having at least one effect selected from the group consisting of:
[78] The treatment method according to any one of
[72] to
[77] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody.
[79] The treatment method described in
[78] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[80] The treatment method described in
[78] or
[79] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.
[81] The treatment method described in
[78] or
[79] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.
[82] The treatment method according to any one of
[72] to
[81] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 2 to 8.
[83] The treatment method according to any one of
[72] to
[81] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.
[84] The treatment method according to any one of
[72] to
[81] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7.5 to 8.
[85] The method for treating a disease according to any one of
[72] to
[84] , wherein the disease is at least one selected from the group consisting of lung cancer, urothelial carcinoma, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
[86] The treatment method according to
[85] , wherein the disease is colorectal cancer.
[87] The treatment method according to
[85] , wherein the disease is breast cancer.
[88] formula
[0021] [ka]
[0022] A method for treating a disease which can be improved by the action of releasing a compound represented by the formula (I) into a tumor and activating antitumor immunity.
[89] The compound is (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells The treatment method described in
[88] , having at least one effect selected from the group consisting of:
[90] The treatment method described in
[88] or
[89] , wherein the compound has the effect of promoting immune memory formation against a tumor.
[91] The compound is (1) Promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; The method for treatment according to any one of
[88] to
[90] , having at least one effect selected from the group consisting of:
[92] The method for treating a disease according to any one of
[88] to
[91] , wherein the disease is at least one selected from the group consisting of lung cancer, urothelial carcinoma, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
[93] To treat diseases by administering in combination with immune checkpoint inhibitors. formula
[0023] [ka]
[0024] (wherein A represents the binding site to the antibody) An antibody-drug conjugate in which a drug linker represented by the formula:
[94] The antibody-drug conjugate according to
[93] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody.
[95] The antibody-drug conjugate according to
[94] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[96] The antibody-drug conjugate according to
[94] or
[95] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.
[97] The antibody-drug conjugate according to
[94] or
[95] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.
[98] The antibody-drug conjugate according to any one of
[93] to
[97] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 2 to 8.
[99] The antibody-drug conjugate according to any one of
[93] to
[97] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.
[0100] The antibody-drug conjugate according to any one of
[93] to
[97] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7.5 to 8.
[0101] The antibody-drug conjugate described in any one of
[93] to
[0100] , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.
[0102] The antibody-drug conjugate described in
[0101] , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.
[0103] The antibody-drug conjugate described in
[0101] , wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody.
[0104] The antibody-drug conjugate described in
[0101] , wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody.
[0105] The antibody-drug conjugate described in any one of
[93] to
[0104] , characterized in that the antibody-drug conjugate and the immune checkpoint inhibitor are contained as active ingredients in separate formulations and are administered simultaneously or at different times.
[0106] An antibody-drug conjugate described in any one of
[93] to
[0104] , characterized in that the antibody-drug conjugate and the immune checkpoint inhibitor are contained as active ingredients in a single formulation and administered.
[0107] An antibody-drug conjugate described in any one of
[93] to
[0106] for the treatment of cancer.
[0108] The antibody-drug conjugate according to
[0107] , wherein the cancer is at least one selected from the group consisting of lung cancer, urothelial carcinoma, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
[0109] The antibody-drug conjugate described in
[0108] , wherein the cancer is colorectal cancer.
[0110] The antibody-drug conjugate described in
[0108] , wherein the cancer is breast cancer.
[0111] An antibody-drug conjugate described in any one of
[93] to
[0110] , which has the effect of activating anti-tumor immunity.
[0112] (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells An antibody-drug conjugate described in any one of
[93] to
[0111] , having at least one effect selected from the group consisting of:
[0113] An antibody-drug conjugate described in any one of
[93] to
[0112] , which has the effect of promoting immune memory formation against a tumor.
[0114] An antibody-drug conjugate described in
[0113] , wherein the tumor expresses an antigen against which the antibody in the antibody-drug conjugate is directed.
[0115] An antibody-drug conjugate described in
[0113] , wherein a portion of the tumor does not express an antigen against the antibody in the antibody-drug conjugate.
[0116] (1) Promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; An antibody-drug conjugate described in any one of
[93] to
[0115] , which has at least one effect selected from the group consisting of:
[0117] The antibody-drug conjugate described in any one of
[93] to
[0116] , characterized in that the antibody-drug conjugate exhibits a stronger anti-tumor effect by using an immune checkpoint inhibitor to cancel an immunosuppressive signal generated by promoting an increase in the expression level of PD-L1 on cancer cells.
[0118] For use in the treatment of diseases that are improved by activating antitumor immunity formula
[0025] [ka]
[0026] (wherein A represents the binding site to the antibody) An antibody-drug conjugate in which a drug linker represented by the formula:
[0119] (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells An antibody-drug conjugate described in
[0118] , which has at least one effect selected from the group consisting of:
[0120] An antibody-drug conjugate described in
[0118] or
[0119] , which has the effect of promoting the formation of immune memory against tumors.
[0121] The antibody-drug conjugate of claim
[0120] , wherein the tumor expresses an antigen against which the antibody in the antibody-drug conjugate is directed.
[0122] An antibody-drug conjugate described in
[0120] , wherein a portion of the tumor does not express an antigen against the antibody in the antibody-drug conjugate.
[0123] (1) Promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; An antibody-drug conjugate described in any one of
[0118] to
[0122] for use in treating a disease that is improved by at least one effect selected from the group consisting of:
[0124] An antibody-drug conjugate described in any one of
[0118] to
[0123] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody.
[0125] An antibody-drug conjugate described in
[0124] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[0126] An antibody-drug conjugate described in
[0124] or
[0125] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.
[0127] An antibody-drug conjugate described in
[0124] or
[0125] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.
[0128] An antibody-drug conjugate described in any one of
[0118] to
[0127] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 2 to 8.
[0129] An antibody-drug conjugate described in any one of
[0118] to
[0127] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.
[0130] An antibody-drug conjugate described in any one of
[0118] to
[0127] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7.5 to 8.
[0131] The antibody-drug conjugate according to any one of
[0118] to
[0130] , wherein the disease is at least one selected from the group consisting of lung cancer, urothelial carcinoma, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
[0132] The antibody-drug conjugate described in
[0131] , wherein the disease is colorectal cancer.
[0133] The antibody-drug conjugate described in
[0131] , wherein the disease is breast cancer.
[0134] For use in the treatment of diseases that are improved by the action of activating antitumor immunity by being released into a tumor. formula
[0027] [ka]
[0028] A compound represented by the formula:
[0135] (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells The compound according to
[0134] , having at least one effect selected from the group consisting of:
[0136] A compound described in
[0134] or
[0135] , which has the effect of promoting immune memory formation against tumors.
[0137] (1) Promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; A compound described in any one of
[0134] to
[0136] , having at least one effect selected from the group consisting of:
[0138] The compound according to any one of
[0134] to
[0137] , wherein the disease is at least one selected from the group consisting of lung cancer, urothelial carcinoma, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
[0139] For the manufacture of a medicament for treating a disease by administering in combination with an immune checkpoint inhibitor. formula
[0029] [ka]
[0030] (wherein A represents the binding site to the antibody) and an antibody-drug conjugate in which the drug linker represented by the formula:
[0140] The use described in
[0139] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody.
[0141] The use described in
[0140] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[0142] The use described in
[0140] or
[0141] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.
[0143] The use described in
[0140] or
[0141] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.
[0144] The use described in any one of
[0139] to
[0143] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 2 to 8.
[0145] The use described in any one of
[0139] to
[0143] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.
[0146] The use described in any one of
[0139] to
[0143] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7.5 to 8.
[0147] The use described in any one of
[0139] to
[0146] , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.
[0148] The use described in
[0147] , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.
[0149] The use described in
[0147] , wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody.
[0150] The use described in
[0147] , wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody.
[0151] The use described in any one of
[0139] to
[0150] , characterized in that the antibody-drug conjugate and the immune checkpoint inhibitor are contained as active ingredients in separate formulations and are administered simultaneously or at different times.
[0152] The use described in any one of
[0139] to
[0150] , characterized in that the antibody-drug conjugate and the immune checkpoint inhibitor are contained as active ingredients in a single formulation and administered.
[0153] A use described in any one of
[0139] to
[0152] for the treatment of cancer.
[0154] The use according to
[0153] , wherein the cancer is at least one selected from the group consisting of lung cancer, urothelial carcinoma, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
[0155] The use described in
[0154] , wherein the cancer is colon cancer.
[0156] The use described in
[0154] , wherein the cancer is breast cancer.
[0157] The use described in any one of
[0139] to
[0156] , wherein the antibody-drug conjugate has the effect of activating anti-tumor immunity.
[0158] The antibody-drug conjugate is (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells The use described in any one of
[0139] to
[0157] , having at least one effect selected from the group consisting of:
[0159] The use described in any one of
[0139] to
[0158] , wherein the antibody-drug conjugate has the effect of promoting immune memory formation against a tumor.
[0160] The use described in
[0159] , wherein the tumor expresses an antigen against which the antibody in the antibody-drug conjugate is directed.
[0161] The use described in
[0159] , wherein a portion of the tumor does not express an antigen against the antibody in the antibody-drug conjugate.
[0162] The antibody-drug conjugate is (1) Promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; The use described in any one of
[0139] to
[0161] , having at least one effect selected from the group consisting of:
[0163] The use described in any one of
[0139] to
[0162] , wherein the antibody-drug conjugate exhibits a stronger anti-tumor effect by releasing an immunosuppressive signal generated by the antibody-drug conjugate promoting an increase in the expression level of PD-L1 on cancer cells, with the immune checkpoint inhibitor thereby eliminating the immunosuppressive signal.
[0164] For the manufacture of a medicine for treating a disease that is improved by activating antitumor immunity formula
[0031] [ka]
[0032] (wherein A represents the binding site to the antibody) and an antibody-drug conjugate in which the drug linker represented by the formula:
[0165] The antibody-drug conjugate is (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells The use described in
[0164] , having at least one effect selected from the group consisting of:
[0166] The use described in
[0164] or
[0165] , wherein the antibody-drug conjugate has the effect of promoting immune memory formation against a tumor.
[0167] The use described in claim
[0166] , wherein the tumor expresses an antigen against which the antibody in the antibody-drug conjugate is directed.
[0168] The use described in
[0166] , wherein a portion of the tumor does not express an antigen against the antibody in the antibody-drug conjugate.
[0169] (1) Promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; The use described in any one of
[0164] to
[0168] for the manufacture of a medicament for use in the treatment of a disease that is improved by at least one effect selected from the group consisting of:
[0170] The use described in any one of
[0164] to
[0169] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody.
[0171] The use described in
[0170] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
[0172] The use described in
[0170] or
[0171] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.
[0173] The use described in
[0170] or
[0171] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.
[0174] The use described in any one of
[0164] to
[0173] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 2 to 8.
[0175] The use described in any one of
[0164] to
[0173] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.
[0176] The use described in any one of
[0164] to
[0173] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7.5 to 8.
[0177] The use described in any one of
[0164] to
[0176] , wherein the disease is at least one selected from the group consisting of lung cancer, urothelial carcinoma, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
[0178] The use described in
[0177] , wherein the disease is colon cancer.
[0179] The use described in
[0177] , wherein the disease is breast cancer.
[0180] formula
[0033] [ka]
[0034] 2. Use of a compound represented by the following formula (1):
[0181] The compound is (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells The use described in
[0180] , having at least one effect selected from the group consisting of:
[0182] The use described in
[0180] or
[0181] , wherein the compound has the effect of promoting immune memory formation against a tumor.
[0183] The compound is (1) Promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; The use described in any one of
[0180] to
[0182] , having at least one effect selected from the group consisting of:
[0184] The use according to any one of
[0180] to
[0183] , wherein the disease is at least one selected from the group consisting of lung cancer, urothelial carcinoma, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
[0035] Regarding. Effect of the Invention
[0036] According to the present invention, a pharmaceutical composition and a treatment method that are excellent in antitumor effect and safety by administering a specific antibody-drug conjugate in combination with an immune checkpoint inhibitor can be provided. In addition, according to the present invention, a pharmaceutical composition and a treatment method for treating a disease that is improved by the action of promoting immune memory formation against a tumor can be provided, which are characterized by containing a specific antibody-drug conjugate. [Brief description of the drawings]
[0037] [Figure 1] 1 shows the amino acid sequence of the humanized anti-HER2 antibody heavy chain (SEQ ID NO:1). [Diagram 2] 1 shows the amino acid sequence of the humanized anti-HER2 antibody light chain (SEQ ID NO:2). [Diagram 3]This figure shows the survival benefit of each drug in mice subcutaneously implanted with CT26.WT-hHER2 cells. The survival benefit was compared between the antibody-drug conjugate (1) and anti-PD-1 antibody (clone RMP1-14) monotherapy group and the combined therapy group. [Figure 4] This figure shows the survival benefit of each drug in mice subcutaneously implanted with CT26.WT-hHER2 cells. The survival benefit was compared between the antibody-drug conjugate (1) and anti-PD-1 antibody (clone RMP1-14) monotherapy group and the combined therapy group. [Diagram 5] FIG. 1 shows the time course of tumor volume when CT26.WT-hHER2 cells or CT26.WT-mock cells were subcutaneously transplanted (re-transplanted) into cured mice treated with antibody-drug conjugate (1) and into control mice. [Figure 6] FIG. 1 shows immune responses (number of IFNγ-producing spleen cells) against antigens derived from CT26.WT-hHER2 cells in cured mice treated with antibody-drug conjugate (1) and in control mice that were subcutaneously transplanted (retransplanted) with CT26.WT-hHER2 cells. [Figure 7] FIG. 1 shows immune responses (number of IFNγ-producing spleen cells) against antigens derived from CT26.WT-mock cells in cured mice treated with antibody-drug conjugate (1) and in control mice subcutaneously transplanted (re-transplanted) with CT26.WT-hHER2 cells. [Figure 8] FIG. 1 shows immune responses (number of IFNγ-producing spleen cells) against antigens derived from CT26.WT-hHER2 cells in cured mice treated with antibody-drug conjugate (1) and in control mice subcutaneously transplanted (re-transplanted) with CT26.WT-mock cells. [Figure 9] FIG. 1 shows immune responses (number of IFNγ-producing spleen cells) against antigens derived from CT26.WT-mock cells in cured mice treated with antibody-drug conjugate (1) and in control mice, where CT26.WT-mock cells were subcutaneously transplanted (retransplanted). [Figure 10] FIG. 1 shows the results of flow cytometry measurement of CD86 expression levels in bone marrow-derived dendritic cells treated with compound (A) and DMSO. [Figure 11] FIG. 1 shows the results of flow cytometry measurement of MHC class II expression levels in bone marrow-derived dendritic cells treated with compound (A) and DMSO. [Figure 12] FIG. 13 shows the results of measuring, by flow cytometry, the number of dendritic cells among intratumoral lymphocytes in the antibody-drug conjugate (1) administration group and the control group in mice subcutaneously implanted with CT26.WT-hHER2 cells. [Figure 13] FIG. 13 shows the results of measuring, by flow cytometry, the number of CD86-positive cells among intratumoral dendritic cells in the antibody-drug conjugate (1) administration group and the control group in mice subcutaneously implanted with CT26.WT-hHER2 cells. [Figure 14] FIG. 1 shows the expression levels of CD86 on intratumoral dendritic cells in mice subcutaneously implanted with CT26.WT-hHER2 cells, measured by flow cytometry for the antibody-drug conjugate (1) administration group and the control group, and the results are shown as MFI. [Figure 15] FIG. 1 shows the expression levels of MHC class I on cancer cells (human HER2-positive cells) in mice subcutaneously implanted with CT26.WT-hHER2 cells, measured by flow cytometry for the antibody-drug conjugate (1) administration group and the control group, and the results are shown as MFI. [Figure 16] This figure shows the expression levels of PD-L1 on cancer cells (human HER2-positive cells) in mice subcutaneously implanted with CT26.WT-hHER2 cells, measured by flow cytometry for the antibody-drug conjugate (1) administration group and the control group, and plotted as MFI. [Figure 17] FIG. 1 shows the results of flow cytometry measurement of MHC class I expression levels in cancer cells treated with compound (A) and DMSO. [Figure 18]FIG. 1 shows the time course of tumor volume in the antibody-drug conjugate (1) administration group and the control group in a mouse model in which CT26.WT-hHER2 cells were subcutaneously implanted into nude mice. [Figure 19] FIG. 1 shows the time course of tumor volume in mice subcutaneously implanted with CT26.WT-hHER2 cells for the antibody-drug conjugate (1) administration group, the control antibody-drug conjugate administration group, and the control group. [Figure 20] This figure shows the time course of tumor volume in mice subcutaneously implanted with EMT6-hHER2 cells, for the antibody-drug conjugate (1) and anti-PD-1 antibody (clone RMP1-14) monotherapy and combination therapy groups. [Figure 21] This figure shows the survival benefit of each drug in mice subcutaneously implanted with CT26.WT-hHER2 cells. The survival benefit was compared between the monotherapy and combination therapy groups of antibody-drug conjugate (1) and anti-PD-L1 antibody (clone 10F.9G2). [Figure 22] This figure shows the survival benefit of each drug in mice subcutaneously implanted with EMT6-hHER2 cells. The survival benefit is compared between the antibody-drug conjugate (1) and anti-PD-L1 antibody (clone 10F.9G2) administered alone and in combination with each other. [Figure 23] FIG. 1 shows the time course of tumor volume in mice subcutaneously implanted with CT26.WT-hHER2 cells, for groups administered antibody-drug conjugate (1) and anti-CD4 antibody alone and in combination. [Figure 24] FIG. 1 shows the time course of tumor volume in mice subcutaneously implanted with CT26.WT-hHER2 cells, for groups administered antibody-drug conjugate (1) and anti-CD8 antibody alone and in combination. [Diagram 25] FIG. 13 shows the proportion of CD8 positive T cells among live cells in the tumor, measured by flow cytometry, for the antibody-drug conjugate (1) administration group and the control group in mice subcutaneously implanted with CT26.WT-hHER2 cells. [Figure 26] FIG. 13 shows the proportion of Granzyme B positive cells among intratumoral CD8 positive T cells measured by flow cytometry for the antibody-drug conjugate (1) administration group and the control group in mice subcutaneously implanted with CT26.WT-hHER2 cells. [Figure 27] FIG. 13 shows the proportion of Granzyme B-positive CD8-positive T cells among live cells in the tumor, measured by flow cytometry, for the antibody-drug conjugate (1) administration group and the control group in mice subcutaneously implanted with CT26.WT-hHER2 cells. [Figure 28] FIG. 13 shows the results of flow cytometry measurement of the proportion of CD4-positive T cells among live cells in the tumor for the antibody-drug conjugate (1) administration group and the control group in mice subcutaneously implanted with CT26.WT-hHER2 cells. [Figure 29] FIG. 1 shows images of excised tumors stained with anti-CD8 antibody from the antibody-drug conjugate (1) administration group and the control group in mice subcutaneously implanted with CT26.WT-hHER2 cells. [Diagram 30] FIG. 1 shows the number of CD8 positive cells per unit area in the tumor, determined by analyzing images of excised tumors stained with anti-CD8 antibody in the antibody-drug conjugate (1) administration group and control group in mice subcutaneously implanted with CT26.WT-hHER2 cells. [Diagram 31] FIG. 1 shows the results of flow cytometry measurement of MHC class I expression levels in cancer cells treated with compound (A), DM1-SMe, DM4-SMe, MMAE, and DMSO. [Diagram 32] FIG. 1 shows the time course of tumor volume in mice subcutaneously implanted with EMT6-hHER2 cells, for groups administered either antibody-drug conjugate (1) or anti-CTLA-4 antibody (clone 9H10) alone or in combination. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0038] Hereinafter, preferred embodiments for carrying out the present invention will be described with reference to the drawings. Note that the embodiment described below shows one example of a typical embodiment of the present invention, and the scope of the present invention is not to be interpreted narrowly by this embodiment.
[0039] [Antibody-drug conjugates] The antibody-drug conjugate used in the present invention has the formula
[0040] [ka]
[0041] (wherein A represents the binding site to the antibody) and an antibody via a thioether bond.
[0042] In the present invention, a partial structure of an antibody-drug conjugate consisting of a linker and a drug is referred to as a "drug linker". This drug linker is bonded to a thiol group (in other words, a sulfur atom of a cysteine residue) generated at disulfide bond sites between antibody chains (two sites between heavy chains and two sites between heavy chains and light chains).
[0043] The drug linker of the present invention is based on the topoisomerase I inhibitor exatecan (IUPAC name: (1S,9S)-1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione, (chemical name: (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione)). Exatecan has the formula
[0044] [ka]
[0045] It is a camptothecin derivative having an antitumor effect, represented by the following formula:
[0046] The antibody-drug conjugate used in the present invention may also be represented by the following formula:
[0047] [ka]
[0048] Here, the drug linker is bound to the antibody via a thioether bond, and n is synonymous with the so-called average drug binding number (DAR; Drug-to-Antibody Ratio), and indicates the average number of drug linkers bound per antibody.
[0049] The antibody-drug conjugate used in the present invention has the effect of activating anti-tumor immunity.
[0050] In the present invention, "activating anti-tumor immunity" refers to promoting the exertion of anti-tumor effects by activating at least one selected from the group consisting of T cells and B cells (Bracci L. et al., Cell Death Differ. (2014) 21, 15-25; Chen DS. Et al., Immunity (2013) 39, 1-10; Andersen MH. et al., Journal of Investigative Dermatology (2006) 126, 32-41).
[0051] The fact that the antibody-drug conjugate used in the present invention promotes the exertion of an anti-tumor effect by activating at least one selected from the group consisting of T cells and B cells can be confirmed by comparing the anti-tumor effect of the antibody-drug conjugate used in the present invention in mice with normal immune function with the anti-tumor effect in mice (nude mice) in which the immune functions of T cells and B cells are impaired.
[0052] The antibody-drug conjugate used in the present invention is (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells It has at least one effect selected from the group consisting of:
[0053] The "action of promoting the increase of intratumoral CD8-positive T cells" of the antibody-drug conjugate used in the present invention can be confirmed, for example, by measuring the proportion of CD45, CD3, and CD8-positive cells (CD8-positive T cells) in live cells in the antibody-drug conjugate-administered group and the control group in tumor-bearing mice using flow cytometry, and examining the increase rate. It can also be confirmed by analyzing images of excised tumors stained with anti-CD8 antibody in the antibody-drug conjugate-administered group and the control group in tumor-bearing mice, measuring the number of CD8-positive cells per unit area in the tumor, and examining the increase rate.
[0054] The "activity of activating intratumoral CD8-positive T cells" of the antibody-drug conjugate used in the present invention can be confirmed, for example, by measuring the proportion of Granzyme B-positive cells in CD8-positive T cells in a group administered with the antibody-drug conjugate and a control group in tumor-bearing mice using flow cytometry and examining the rate of increase. It can also be confirmed by measuring the proportion of Granzyme B-positive cells in live cells using flow cytometry and examining the rate of increase.
[0055] The antibody-drug conjugate used in the present invention has the effect of promoting the formation of immune memory against tumors, which contributes to the above-mentioned "effect of activating anti-tumor immunity."
[0056] T cells are activated when tumor-derived antigens are presented to them by dendritic cells or cancer cells, thereby eliciting an immune response and exerting an antitumor effect.
[0057] In the present invention, "immune memory formation against a tumor" refers to the formation of memory of an immune response against a tumor by generating memory T cells from T cells upon presentation of a tumor-derived antigen, which allows a sustained antitumor effect against a tumor having the antigen, and also allows the antitumor effect to be exerted again when a tumor having the antigen recurs.
[0058] The "effect of promoting immune memory formation against tumors" of the antibody-drug conjugate used in the present invention can be confirmed, for example, by administering the antibody-drug conjugate to a cancer-bearing mouse, transplanting the tumor back into the mouse in which the tumor has completely regressed, and measuring the degree of inhibition of tumor growth (recurrence). It can also be confirmed by removing the spleen from the above-mentioned mouse, adding a tumor-derived antigen, and measuring the rate of increase in immune response (for example, the number of IFNγ-producing spleen cells).
[0059] The antibody-drug conjugate used in the present invention has the effect of promoting immune memory formation not only in tumors expressing an antigen against the antibody in the antibody-drug conjugate, but also in tumors in the same individual that do not express an antigen against the antibody in the antibody-drug conjugate.
[0060] For example, when the antibody in the antibody-drug conjugate is an anti-HER2 antibody, it not only has the effect of promoting immune memory formation against tumors expressing HER2, but also has the effect of promoting immune memory formation against tumors that do not express HER2 within the same individual.
[0061] The antibody-drug conjugate used in the present invention is (1) Promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; It has at least one effect selected from the group consisting of: These actions contribute to the above-mentioned "action of promoting immune memory formation against tumors" and, in turn, contribute to the above-mentioned "action of activating anti-tumor immunity."
[0062] The "effect of promoting an increase in the number of dendritic cells in a tumor" of the antibody-drug conjugate used in the present invention can be confirmed, for example, by measuring the proportion of CD11c, MHC class II, CD45 positive cells (dendritic cells, DC) among CD45 positive cells (lymphocytes) using flow cytometry in an antibody-drug conjugate-administered group and a control group in tumor-bearing mice, and examining the rate of increase.
[0063] The "effect of activating dendritic cells" of the antibody-drug conjugate used in the present invention can be confirmed, for example, by measuring the proportion of dendritic cells expressing CD86 (activation marker) using flow cytometry and examining the rate of increase in an antibody-drug conjugate-administered group and a control group in cancer-bearing mice. It can also be confirmed by measuring the expression level (MFI (mean fluorescence intensity)) of CD86 on dendritic cells by flow cytometry and examining the rate of increase in an antibody-drug conjugate-administered group and a control group in cancer-bearing mice.
[0064] The "effect of promoting an increase in the expression level of MHC class I on cancer cells" of the antibody-drug conjugate used in the present invention can be confirmed, for example, by measuring the expression level (MFI) of MHC class I on cancer cells in an antibody-drug conjugate-administered group and a control group in cancer-bearing mice by flow cytometry and examining the rate of increase.
[0065] The antibody-drug conjugate used in the present invention may have the effect of promoting an increase in the expression level of PD-L1 on cancer cells. The immune checkpoint inhibitor releases the immunosuppressive signal generated by this, allowing the antibody-drug conjugate to exhibit a stronger antitumor effect. Therefore, the antibody-drug conjugate used in the present invention can be expected to have a stronger antitumor effect when used in combination with an immune checkpoint inhibitor.
[0066] The "effect of promoting an increase in the expression level of PD-L1 on cancer cells" of the antibody-drug conjugate used in the present invention can be confirmed, for example, by measuring the expression level (MFI) of PD-L1 on cancer cells in an antibody-drug conjugate-administered group and a control group in cancer-bearing mice by flow cytometry and examining the rate of increase.
[0067] The antibody-drug conjugate used in the present invention is transported into cancer cells, and then the linker moiety is cleaved,
[0068] formula
[0069] [ka]
[0070] (hereinafter referred to as "compound (A)") is released.
[0071] Compound (A) is considered to be the main component of the antitumor activity of the antibody-drug conjugate used in the present invention, and has been confirmed to have a topoisomerase I inhibitory effect (Ogitani Y. et al., Clinical Cancer Research, 2016, Oct 15;22(20):5097-5108, Epub 2016 Mar 29).
[0072] Compound (A) has the effect of activating dendritic cells and promoting an increase in the amount of MHC class I expressed on cancer cells.
[0073] The "effect of activating dendritic cells" of compound (A) can be confirmed, for example, by treating bone marrow-derived dendritic cells with compound (A) and DMSO, measuring the expression level of CD86 by flow cytometry, and examining the rate of increase.
[0074] The "effect of compound (A) of promoting an increase in the expression level of MHC class I on cancer cells" can be confirmed, for example, by measuring the expression level of MHC class I by flow cytometry when cancer cells are treated with compound (A) and DMSO, and examining the rate of increase.
[0075] The "effect of activating dendritic cells" and the "effect of promoting an increase in the expression level of MHC class I on cancer cells" of compound (A) are the same effects as the "effect of activating dendritic cells" and the "effect of promoting an increase in the expression level of MHC class I on cancer cells" of the antibody-drug conjugate used in the present invention. As described above, compound (A) is a compound that is released from the antibody-drug conjugate used in the present invention after the antibody-drug conjugate used in the present invention migrates into cancer cells.
[0076] Therefore, the pharmaceutical composition that releases compound (A) in a tumor can be prepared as follows, similar to the antibody-drug conjugate used in the present invention: (1) Promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; It is expected that the compound has at least one effect selected from the group consisting of:
[0077] Furthermore, a pharmaceutical composition that releases compound (A) within a tumor is expected to have the effect of promoting the formation of immune memory against a tumor, similar to the antibody-drug conjugate used in the present invention.
[0078] As described above, compound (A) is a compound produced from the antibody-drug conjugate used in the present invention after the antibody-drug conjugate used in the present invention migrates into cancer cells.
[0079] Therefore, the pharmaceutical composition that releases compound (A) in a tumor can be prepared as follows, similar to the antibody-drug conjugate used in the present invention: (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells It is expected to have at least one effect selected from the group consisting of Ultimately, it is expected to have the "effect of activating anti-tumor immunity."
[0080] In addition, the antibody-drug conjugate used in the present invention is also known to have a bystander effect (Ogitani Y. et al., Cancer Science (2016) 107, 1039-1046). This bystander effect is exerted when the antibody-drug conjugate used in the present invention is internalized into a target-expressing cancer cell, and the released compound (A) exerts an antitumor effect even on nearby cancer cells that do not express the target. The bystander effect of the antibody-drug conjugate used in the present invention is exerted as an excellent antitumor effect even when used in combination with an immune checkpoint inhibitor. [Antibodies used in the production of antibody-drug conjugates] The antibody used in the preparation of the antibody-drug conjugate of the present invention may be derived from any species, but is preferably derived from human, rat, mouse, or rabbit. If the antibody is derived from a species other than human, it is preferably chimerized or humanized using well-known techniques. The antibody of the present invention may be a polyclonal or monoclonal antibody, but is preferably a monoclonal antibody.
[0081] The antibody used in the production of the antibody-drug conjugate according to the present invention preferably has the property of targeting cancer cells, and preferably has the property of recognizing cancer cells, the property of binding to cancer cells, the property of being taken up and internalized within cancer cells, and / or cytocidal activity against cancer cells.
[0082] The binding of the antibody to the cancer cells can be confirmed by flow cytometry. The uptake of the antibody into the cancer cells can be confirmed by (1) an assay in which the antibody taken up into the cells is visualized by a fluorescence microscope using a secondary antibody (fluorescently labeled) that binds to the therapeutic antibody (Cell Death and Differentiation (2008) 15, 751-761), (2) an assay in which the amount of fluorescence taken up into the cells is measured using a secondary antibody (fluorescently labeled) that binds to the therapeutic antibody (Molecular Biology of the Cell Vol. 15, 5268-5282, December 2004), or (3) a Mab-ZAP assay in which an immunotoxin that binds to the therapeutic antibody is released when the antibody is taken up into the cells, thereby suppressing cell proliferation (Bio Techniques 28:162-165, January 2000). A recombinant complex protein of the catalytic domain of diphtheria toxin and protein G can also be used as the immunotoxin.
[0083] The antitumor activity of an antibody can be confirmed in vitro by measuring the inhibitory activity against cell proliferation. For example, a cancer cell line that overexpresses the antibody's target protein is cultured, and the antibody is added to the culture system at various concentrations to measure the inhibitory activity against focus formation, colony formation, and spheroid proliferation. In vivo, the antitumor activity can be confirmed, for example, by administering the antibody to nude mice transplanted with a cancer cell line that highly expresses the target protein, and measuring the changes in the cancer cells.
[0084] It is preferable that the antibody itself has an antitumor effect, but since the antibody-drug conjugate is bound to a compound that exerts an antitumor effect, the antibody itself does not necessarily have an antitumor effect. For the purpose of exerting the cytotoxicity of the antitumor compound specifically and selectively in cancer cells, it is important and preferable that the antibody has the property of being internalized and transferred into the cancer cells.
[0085] The antibody used in the production of the antibody-drug conjugate according to the present invention can be obtained by known means. For example, it can be obtained by immunizing an animal with an antigenic polypeptide, and collecting and purifying the antibody produced in the body, using a method commonly used in this field. The origin of the antigen is not limited to humans, and an animal can also be immunized with an antigen derived from an animal other than humans, such as a mouse or a rat. In this case, an antibody applicable to a human disease can be selected by testing the cross-reactivity of the obtained antibody that binds to a heterologous antigen with a human antigen.
[0086] Alternatively, a hybridoma can be established by fusing an antibody-producing cell that produces an antibody against an antigen with a myeloma cell according to known methods (e.g., Kohler and Milstein, Nature (1975) 256, p. 495-497; Kennet, R. ed., Monoclonal Antibodies, p. 365-367, Plenum Press, NY (1980)), thereby obtaining a monoclonal antibody.
[0087] The antigen can be obtained by genetically engineering a gene encoding an antigen protein in a host cell to produce it. Specifically, a vector capable of expressing an antigen gene is prepared, introduced into a host cell to express the gene, and the expressed antigen is purified. Antibodies can also be obtained by immunizing an animal with the above genetically engineered antigen-expressing cells or a cell line expressing the antigen.
[0088] The antibody used in the production of the antibody-drug conjugate of the present invention is preferably a genetically engineered antibody that has been artificially modified for the purpose of reducing heterologous antigenicity against humans, such as a chimeric antibody or a humanized antibody, or is preferably an antibody having only the genetic sequence of an antibody derived from humans, i.e., a human antibody. These antibodies can be produced using known methods.
[0089] Chimeric antibodies include antibodies whose variable and constant regions are of different species, such as chimeric antibodies in which the variable region of an antibody derived from a mouse or rat is joined to a constant region derived from a human (Proc. Natl. Acad. Sci. USA, 81, 6851-6855, (1984)).
[0090] Examples of humanized antibodies include antibodies in which only the complementarity determining region (CDR) of a heterologous antibody has been incorporated into an antibody of human origin (Nature (1986) 321, p. 522-525), antibodies in which not only the CDR sequence of a heterologous antibody but also some framework amino acid residues of the heterologous antibody have been grafted onto a human antibody by CDR grafting (WO 90 / 07861), and antibodies humanized using a gene conversion mutagenesis strategy (U.S. Pat. No. 5,821,337).
[0091] Examples of human antibodies include antibodies produced using human antibody-producing mice having a human chromosome fragment containing the heavy and light chain genes of a human antibody (see, for example, Tomizuka, K. et al., Nature Genetics (1997) 16, p.133-143; Kuroiwa, Y. et al., Nucl. Acids Res. (1998) 26, p.3447-3448; Yoshida, H. et al., Animal Cell Technology: Basic and Applied Aspects vol.10, p.69-73 (Kitagawa, Y., Matsuda, T. and Iijima, S. eds.), Kluwer Academic Publishers, 1999; Tomizuka, K. et al., Proc. Natl. Acad. Sci. USA (2000) 97, p.722-727). Alternatively, antibodies obtained by phage display selected from a human antibody library can also be used (see, for example, Wormstone, IM et. al, Investigative Ophthalmology & Visual Science. (2002) 43 (7), p. 2301-2308; Carmen, S. et. al., Briefings in Functional Genomics and Proteomics (2002), 1 (2), p. 189-203; Siriwardena, D. et. al., Ophthalmology (2002) 109 (3), p. 427-431).
[0092] The antibody used in the production of the antibody-drug conjugate according to the present invention also includes modified antibodies. The modified antibody means an antibody according to the present invention that has been chemically or biologically modified. Chemical modifications include those having a chemical moiety bonded to the amino acid backbone, or a chemical moiety bonded to an N- or O-linked carbohydrate chain. Biological modifications include those that have been post-translationally modified (e.g., addition of an N- or O-linked sugar chain, processing of the N- or C-terminus, deamidation, isomerization of aspartic acid, oxidation of methionine, etc.), and those that have been expressed using a prokaryotic host cell to add a methionine residue to the N-terminus. In addition, those labeled to enable detection or isolation of the antibody or antigen according to the present invention, such as enzyme-labeled, fluorescent-labeled, and affinity-labeled, are also included in the meaning of such modified antibodies. Such modified antibodies according to the present invention are useful for improving the stability and blood retention of the antibody, reducing antigenicity, and detecting or isolating the antibody or antigen, etc.
[0093] Furthermore, antibody-dependent cellular cytotoxicity can be enhanced by regulating the sugar chain modification bound to the antibody of the present invention (glycosylation, defucosylation, etc.). Techniques for regulating the sugar chain modification of antibodies are known, including, but not limited to, those disclosed in International Publication Nos. 99 / 54342, 00 / 61739, and 02 / 31140. The antibody of the present invention also includes an antibody in which the sugar chain modification has been regulated.
[0094] It is known that antibodies produced in cultured mammalian cells have a deletion of the lysine residue at the carboxyl terminus of their heavy chains (Journal of Chromatography A, 705: 129-134 (1995)), and also have a deletion of two amino acid residues, glycine and lysine, at the carboxyl terminus of the heavy chain, and amidation of the proline residue located at the carboxyl terminus (Analytical Biochemistry, 360: 75-83 (2007)). However, these deletions and modifications of the heavy chain sequence do not affect the antigen-binding ability and effector functions (complement activation, antibody-dependent cellular cytotoxicity, etc.) of the antibody. Therefore, the antibody according to the present invention also includes antibodies and functional fragments of the antibodies that have been modified in this way, and also includes deletion products in which one or two amino acids have been deleted at the carboxyl terminus of the heavy chain, and deletion products that have been amidated (for example, heavy chains in which the proline residue at the carboxyl terminus has been amidated). However, as long as the antigen-binding ability and effector function are maintained, the deletion of the carboxyl terminus of the heavy chain of the antibody according to the present invention is not limited to the above types. The two heavy chains constituting the antibody according to the present invention may be any one type of heavy chain selected from the group consisting of full-length and the above deletions, or may be a combination of any two types. The quantitative ratio of each deletion may be influenced by the type and culture conditions of the cultured mammalian cells producing the antibody according to the present invention, but the antibody according to the present invention is preferably one in which one amino acid residue is deleted at the carboxyl terminus of both of the two heavy chains.
[0095] The isotype of the antibody according to the present invention can be, for example, IgG (IgG1, IgG2, IgG3, IgG4), etc., and preferably IgG1 or IgG2.
[0096] The antibody that can be used in the production of the antibody-drug conjugate according to the present invention is not particularly limited, and examples thereof include an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-CD3 antibody, an anti-CD30 antibody, an anti-CD33 antibody, an anti-CD37 antibody, an anti-CD56 antibody, an anti-CD98 antibody, an anti-DR5 antibody, an anti-EGFR antibody, an anti-EPHA2 antibody, an anti-FGFR2 antibody, an anti-FGFR4 antibody, an anti-FOLR1 antibody, an anti-VEGF antibody, an anti-CD20 antibody, an anti-CD22 antibody, an anti-CD70 antibody, an anti-PSMA antibody, an anti-CEA antibody, and an anti-Mesothelin antibody, preferably an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, and an anti-B7-H3 antibody, and more preferably an anti-HER2 antibody.
[0097] In the present invention, the term "anti-HER2 antibody" refers to an antibody that specifically binds to HER2 (Human Epidermal Growth Factor Receptor Type 2; ErbB-2), and preferably has the activity of being internalized into HER2-expressing cells upon binding to HER2.
[0098] Examples of anti-HER2 antibodies include trastuzumab (US Pat. No. 5,821,337) and pertuzumab (International Publication No. WO 01 / 00245), and preferably trastuzumab.
[0099] In the present invention, "trastuzumab" is also referred to as HERCEPTIN (registered trademark), huMAb4D5-8, or rhuMAb4D5-8, and is a humanized anti-HER2 antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 (Figure 1) and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2 (Figure 2).
[0100] Suitable anti-HER2 antibodies for use in the preparation of the antibody-drug conjugate of the present invention include: (1) An antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2; or (2) An antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO:1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:2.
[0101] In the present invention, the term "anti-HER3 antibody" refers to an antibody that specifically binds to HER3 (Human Epidermal Growth Factor Receptor Type 3; ErbB-3), and preferably has the activity of being internalized into HER3-expressing cells upon binding to HER3.
[0102] Examples of anti-HER3 antibodies include Patritumab (U3-1287), U1-59 (WO 2007 / 077028), MM-121 (Seribantumab), the anti-ERBB3 antibodies described in WO 2008 / 100624, RG-7116 (Lumretuzumab), and LJM-716 (Elgemtumab), and preferred examples include Patritumab and U1-59.
[0103] In the present invention, the term "anti-TROP2 antibody" refers to an antibody that specifically binds to TROP2 (TACSTD2: Tumor-associated calcium signal transducer 2; EGP-1), and preferably has the activity of being internalized into TROP2-expressing cells by binding to TROP2.
[0104] An example of an anti-TROP2 antibody is hTINA1-H1L1 (WO 2015 / 098099).
[0105] In the present invention, the term "anti-B7-H3 antibody" refers to an antibody that specifically binds to B7-H3, and preferably has the activity of being internalized into B7-H3-expressing cells through binding to B7-H3.
[0106] An example of an anti-B7-H3 antibody is M30-H1-L4 (WO 2014 / 057687). [Drug-Linker Intermediates Used in the Preparation of Antibody-Drug Conjugates] The drug linker intermediate used in the preparation of the antibody-drug conjugate of the present invention is represented by the following formula:
[0107] [ka]
[0108] The drug linker intermediate shown above is N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]glycylglycyl-L-phenylalanyl-N-[(2-{[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de] It can be expressed by the chemical name “pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]amino}-2-oxoethoxy)methyl]glycinamide,” and can be produced by referring to the descriptions in WO 2014 / 057687, WO 2015 / 098099, WO 2015 / 115091, WO 2015 / 155998, etc.
[0109] [Conjugation of antibodies and drug-linker intermediates] The antibody-drug conjugate used in the present invention can be prepared by reacting the above-mentioned drug linker intermediate with an antibody having a thiol group (also called a sulfhydryl group).
[0110] An antibody having a sulfhydryl group can be obtained by a method well known to those skilled in the art (Hermanson, G. T, Bioconjugate Techniques, pp.56-136, pp.456-493, Academic Press (1996)). For example, a reducing agent such as tris(2-carboxyethyl)phosphine hydrochloride (TCEP) can be used in an amount of 0.3 to 3 molar equivalents per antibody interchain disulfide, and reacted with the antibody in a buffer containing a chelating agent such as ethylenediaminetetraacetic acid (EDTA), to obtain an antibody having a sulfhydryl group in which the antibody interchain disulfide has been partially or completely reduced.
[0111] Additionally, 2-20 molar equivalents of drug linker intermediate can be used per antibody bearing a sulfhydryl group to produce antibody-drug conjugates with 2-8 drugs attached per antibody.
[0112] The average number of drugs bound per antibody molecule in the produced antibody-drug conjugate can be calculated, for example, by a method in which the UV absorbance of the antibody-drug conjugate and its conjugation precursor are measured at two wavelengths, 280 nm and 370 nm (UV method), or by a method in which the antibody-drug conjugate is treated with a reducing agent, and each of the resulting fragments is quantified by HPLC measurement and then calculated (HPLC method).
[0113] Conjugation of an antibody and a drug linker intermediate, and calculation of the average number of drugs bound per antibody molecule of an antibody-drug conjugate can be performed with reference to the descriptions in WO 2014 / 057687, WO 2015 / 098099, WO 2015 / 115091, WO 2015 / 155998, etc.
[0114] In the present invention, the term "anti-HER2 antibody-drug conjugate" refers to an antibody-drug conjugate in which the antibody is an anti-HER2 antibody.
[0115] The average number of drug linker bonds per antibody in the anti-HER2 antibody-drug conjugate used in the present invention is preferably 2 to 8, more preferably 3 to 8, even more preferably 7 to 8, even more preferably 7.5 to 8, and even more preferably about 8.
[0116] The anti-HER2 antibody-drug conjugate used in the present invention can be produced with reference to the descriptions in WO 2015 / 115091 and the like.
[0117] In the present invention, the term "anti-HER3 antibody-drug conjugate" refers to an antibody-drug conjugate in which the antibody is an anti-HER3 antibody.
[0118] The average number of drug linker bonds per antibody in the anti-HER3 antibody-drug conjugate used in the present invention is preferably 2 to 8, more preferably 3 to 8, even more preferably 7 to 8, even more preferably 7.5 to 8, and even more preferably about 8.
[0119] The anti-HER3 antibody-drug conjugate used in the present invention can be produced with reference to the descriptions in WO 2015 / 155998 and the like.
[0120] In the present invention, the term "anti-TROP2 antibody-drug conjugate" refers to an antibody-drug conjugate in which the antibody is an anti-TROP2 antibody.
[0121] The average number of drug linker bonds per antibody in the anti-TROP2 antibody-drug conjugate used in the present invention is preferably 2 to 8, more preferably 3 to 5, even more preferably 3.5 to 4.5, and even more preferably about 4.
[0122] The anti-TROP2 antibody-drug conjugate used in the present invention can be produced with reference to the descriptions in WO 2015 / 098099 and the like.
[0123] In the present invention, the term "anti-B7-H3 antibody-drug conjugate" refers to an antibody-drug conjugate in which the antibody is an anti-B7-H3 antibody.
[0124] The average number of drug linker bonds per antibody in the anti-B7-H3 antibody-drug conjugate used in the present invention is preferably 2 to 8, more preferably 3 to 5, even more preferably 3.5 to 4.5, and even more preferably about 4.
[0125] The anti-B7-H3 antibody-drug conjugate used in the present invention can be produced with reference to the descriptions in WO 2014 / 057687 and the like.
[0126] [Immune checkpoint inhibitors] In the present invention, the term "immune checkpoint inhibitor" refers to a drug that inhibits the immunosuppressive system and activates tumor immunity.
[0127] The immune checkpoint inhibitor used in the present invention is not particularly limited, but preferred examples include anti-PD-1 antibodies, anti-PD-L1 antibodies, and anti-CTLA-4 antibodies, and more preferred examples include anti-PD-1 antibodies and anti-PD-L1 antibodies.
[0128] In the present invention, the term "anti-PD-1 antibody" refers to an antibody that specifically binds to PD-1 (Programmed cell death-1; CD279; PDCD1) and thereby reduces, inhibits, and / or interferes with signal transduction resulting from the interaction between PD-1 and its binding partners, PD-L1 and PD-L2. The anti-PD-1 antibody used in the present invention is not particularly limited as long as its clinical efficacy and safety have been confirmed, and preferred examples include Nivolumab (WO 2006 / 121168, etc.) and Pembrolizumab (WO 2008 / 156712, etc.). In addition, commercially available research anti-PD-1 antibodies (e.g., clone RMP1-14) and the like can also be used for the purpose of confirming the combined effect of the antibody-drug conjugate used in the present invention in preclinical research.
[0129] In the present invention, the term "anti-PD-L1 antibody" refers to an antibody that specifically binds to PD-L1 (Programmed cell death ligand 1; CD274; B7-H1) and thereby reduces, inhibits, and / or interferes with signal transduction resulting from the interaction of PD-L1 with its binding partners, PD-1 and B7.1 (CD80). There are no particular limitations on the anti-PD-L1 antibody used in the present invention as long as its clinical efficacy and safety have been confirmed, and preferred examples include atezolizumab (WO 2010 / 077634, etc.), durvalumab (WO 2011 / 066389, etc.), and avelumab (WO 2013 / 079174, etc.). In addition, commercially available research-use anti-PD-L1 antibodies (e.g., clone 10F.9G2) and the like can also be used to confirm the combined effects of the antibody-drug conjugates used in the present invention in preclinical studies.
[0130] In the present invention, the term "anti-CTLA-4 antibody" refers to an antibody that specifically binds to CTLA-4 (cytotoxic T-lymphocyte-associated protein 4; CD152) and thereby reduces, inhibits, and / or interferes with signal transduction resulting from the interaction between CTLA-4 and its binding partners, B7.1 (CD80) and B7.2 (CD86). The anti-CTLA-4 antibody used in the present invention is not particularly limited as long as its clinical efficacy and safety have been confirmed, and preferred examples include ipilimumab (WO 2001 / 014424, etc.) and tremelimumab (WO 2000 / 037504, etc.). In addition, commercially available research anti-CTLA-4 antibodies (e.g., clone 9H10) and the like can also be used for the purpose of confirming the combined effect of the antibody-drug conjugate used in the present invention in preclinical research.
[0131] [Medicine] Hereinafter, a pharmaceutical composition and a treatment method characterized by administering a combination of the antibody-drug conjugate according to the present invention and an immune checkpoint inhibitor, as well as a pharmaceutical composition and a treatment method containing the antibody-drug conjugate according to the present invention and used for treating a disease that is ameliorated by the effect of activating anti-tumor immunity, will be described.
[0132] The pharmaceutical composition and treatment method of the present invention may be characterized in that the antibody-drug conjugate and the immune checkpoint inhibitor are contained as active ingredients in different preparations and administered simultaneously or at different times, or in that the antibody-drug conjugate and the immune checkpoint inhibitor are contained as active ingredients in a single preparation and administered. Also, for the treatment of a disease that is improved by the action of activating anti-tumor immunity, the antibody-drug conjugate according to the present invention may be contained as an active ingredient in a single preparation and administered.
[0133] The pharmaceutical composition and treatment method of the present invention can be used for the treatment of cancer, and can be preferably used for the treatment of at least one disease selected from the group consisting of lung cancer (including non-small cell lung cancer), urothelial cancer, colon cancer (sometimes referred to as colorectal cancer, including colon cancer and rectal cancer), prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer (sometimes referred to as gastric adenocarcinoma), gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
[0134] The pharmaceutical composition and treatment method of the present invention can be selected and used as a drug for drug therapy, which is the main treatment for cancer, and as a result, it can delay the growth of cancer cells, suppress their proliferation, and even destroy them. These actions can relieve cancer patients from symptoms caused by cancer and improve their QOL, and the treatment effect can be achieved while preserving the life of the cancer patient. Even if the destruction of cancer cells is not achieved, the inhibition and control of the proliferation of cancer cells can help cancer patients achieve a higher QOL and longer survival.
[0135] In addition to being used alone in such drug therapy, the pharmaceutical composition and treatment method of the present invention can also be used as a drug to be combined with other therapies in adjuvant therapy, and can be combined with surgery, radiation therapy, hormone therapy, etc. Furthermore, it can also be used as a drug for drug therapy in neoadjuvant therapy.
[0136] In addition to the above therapeutic uses, the pharmaceutical composition and treatment method of the present invention can be expected to have a preventive effect of suppressing and even destroying the proliferation of minute metastatic cancer cells. For example, it can be expected to have an effect of suppressing and destroying cancer cells in body fluids during the metastasis process, and an effect of suppressing and destroying minute cancer cells immediately after implantation in any tissue. Therefore, it can be expected to have an effect of suppressing and preventing cancer metastasis, especially after surgical removal of cancer.
[0137] The pharmaceutical composition and treatment method of the present invention can be applied to patients as a systemic therapy, and also can be applied locally to cancer tissues to be expected to have a therapeutic effect.
[0138] The pharmaceutical composition and treatment method of the present invention can be suitably used in mammals, and more suitably used in humans.
[0139] The pharmaceutical composition of the present invention may be administered as a pharmaceutical composition containing one or more pharma- ceutical compatible ingredients. The substances used in the pharmaceutical composition of the present invention may be appropriately selected from formulation additives and other substances commonly used in this field in terms of dosage amount and administration concentration and applied. For example, the pharmaceutical composition typically contains one or more pharmaceutical carriers (e.g., a sterile liquid). Here, the liquid includes, for example, water and oil (petroleum, animal, vegetable, or synthetic oils). The oil may be, for example, peanut oil, soybean oil, mineral oil, sesame oil, etc. Water is a more typical carrier when the pharmaceutical composition is administered intravenously. Saline solution, and aqueous dextrose and glycerol solutions may also be used as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients may be appropriately selected from those known in the art. The composition may also contain minor amounts of wetting or emulsifying agents, or pH buffering agents, if desired. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by EW Martin. The formulation corresponds to the mode of administration.
[0140] Various delivery systems are known and can be used to administer the pharmaceutical composition of the present invention. Introduction routes can include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, and subcutaneous routes. Administration can be, for example, by infusion or bolus injection. In certain preferred embodiments, administration of the antibody-drug conjugates and immune checkpoint inhibitors used in the present invention is by infusion. Parenteral administration is the preferred administration route.
[0141] In a representative embodiment, the pharmaceutical composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to humans. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. If necessary, the pharmaceutical composition may also include a solubilizing agent and a local anesthetic (e.g., lignocaine) to ease pain at the site of injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, e.g., as a dry lyophilized powder or water-free concentrate in a hermetically sealed container, such as an ampule or sachette indicating the quantity of active agent. When the pharmaceutical composition is in a form to be administered by injection, it can be dispensed, for example, in an infusion bottle containing sterile pharmaceutical grade water or saline. When the pharmaceutical composition is administered by injection, an ampoule of sterile water for injection or saline can be provided, for example, so that the ingredients can be mixed prior to administration.
[0142] The pharmaceutical composition and treatment method of the present invention may contain a cancer therapeutic agent other than the antibody-drug conjugate and immune checkpoint inhibitor of the present invention. The pharmaceutical composition and treatment method of the present invention may be administered in combination with other cancer therapeutic agents, thereby enhancing the antitumor effect. The other cancer therapeutic agents used for such purposes may be administered to an individual simultaneously with the pharmaceutical composition of the present invention, separately, or consecutively, or may be administered at different administration intervals. Examples of such cancer therapeutic agents include 5-fluorouracil (5-FU), pertuzumab, trastuzumab, paclitaxel, carboplatin, cisplatin, gemcitabine, capecitabine, irinotecan (CPT-11), docetaxel, and the like. Axel, Pemetrexed, Sorafenib, Vinblastin, Vinorelbine, Everolims, Tanespimycin, Bevacizumab, Oxaliplatin, Lapatinib, Trastuzumab emtansine Examples of such agents include T-DM1, T-DM1 inhibitors, or agents described in WO 2003 / 038043, as well as LH-RH analogues (leuprorelin, goserelin, etc.), estramustine phosphate, estrogen antagonists (tamoxifen, raloxifene, etc.), aromatase inhibitors (anastrozole, letrozole, exemestane, etc.), but are not limited thereto as long as they are agents having antitumor activity.
[0143] Such pharmaceutical compositions can be formulated as lyophilized or liquid preparations with a selected composition and required purity. When formulated as a lyophilized preparation, it may be a preparation containing appropriate formulation additives used in this field. Similarly, liquid preparations can be formulated as liquid preparations containing various formulation additives used in this field.
[0144] Although the composition and concentration of the pharmaceutical composition vary depending on the administration method, the antibody-drug conjugate and immune checkpoint inhibitor contained in the pharmaceutical composition of the present invention can exert their medicinal effects even at a small dose, in terms of affinity to an antigen, i.e., dissociation constant (Kd value) to the antigen, the higher the affinity (lower the Kd value). Therefore, the dose of the antibody-drug conjugate and immune checkpoint inhibitor can be set based on the affinity to the antigen. When the antibody-drug conjugate and immune checkpoint inhibitor according to the present invention are administered to humans, for example, about 0.001 to 100 mg / kg may be administered once or multiple times at intervals of once every 1 to 180 days.
[0145] In the case of the antibody-drug conjugate according to the present invention, for example, an administration method can be a method of administering 0.8 mg / kg to 8 mg / kg once every three weeks. Examples of the dosage can be 0.8 mg / kg, 1.6 mg / kg, 3.2 mg / kg, 5.4 mg / kg, 6.4 mg / kg, 7.4 mg / kg, or 8 mg / kg. The administration may be once every three weeks (q3w), but may also be once a week (q1w), once every two weeks (q2w), or once every four weeks (q4w). EXAMPLES
[0146] The present invention will be specifically described with reference to the following examples, but the present invention is not limited thereto. Furthermore, the examples should not be construed as being limiting in any sense.
[0147] [Production Example 1: Preparation of antibody-drug conjugate] According to the method for producing the present invention described in WO 2015 / 115091, a humanized anti-HER2 antibody (trastuzumab) is used to produce a compound of the formula:
[0148] [ka]
[0149] (wherein A represents the binding site to the antibody) An antibody-drug conjugate (hereinafter referred to as "antibody-drug conjugate (1)") was produced in which an anti-HER2 antibody was bound to a drug linker represented by the following formula via a thioether bond.
[0150] [Production Example 2: Preparation of Compound (A)] According to the method described in WO 2014 / 057687,
[0151] [ka]
[0152] A compound represented by the following formula (compound (A)) was prepared.
[0153] [Evaluation example 1: Life extension test] Mice: Six-week-old female BALB / c mice (BALB / c AnNCrlCrlj) (Charles River Laboratories Japan) were used in the experiment. Measurement and calculation formula: The long and short diameters of the tumor were measured twice a week using an electronic digital caliper (CD15-CX, Mitutoyo Corporation), and the tumor volume (mm 3 ) was calculated using the following formula: Tumor volume (mm 3 ) = 0.5 x major axis (mm) x [minor axis (mm)] 2 Tumor volume 3000 mm 3 Any individuals exceeding this limit were euthanized from the standpoint of animal experiment ethics.
[0154] Antibody-drug conjugate (1) (Drug-to-Antibody Ratio: 7.6) was diluted with a dedicated solvent (10 mM Histidine, 10% Trehalose, 0.02% Polysorbate 20, pH 5.5) before use. Anti-PD-1 antibody (clone RMP1-14) was purchased from Bio X Cell and diluted with DPBS (SIGMA-ALDRICH) before use. The antibody was administered into the tail vein at a dose of 10 mL / kg.
[0155] We used CT26.WT-hHER2 cells, which were prepared by introducing the human HER2 gene into mouse colon cancer cell line CT26.WT (CRL2638) purchased from American Type Culture Collection using a retroviral vector. These cells express human HER2 protein on the cell membrane. CT26.WT-hHER2 cells were suspended in saline and incubated at 5.0 × 10 6 The cells were subcutaneously transplanted into the right axilla of BALB / c mice, and 6 days later, the mice were randomly divided into groups (Day 0). Antibody-drug conjugate (1) was administered twice into the tail vein at a dose of 10 mg / kg on Days 0 and 7. Anti-PD-1 antibody was administered five times into the tail vein at a dose of 2.5 mg / kg on Days 0, 3, 7, 10, and 14. There were also groups administered the antibody-drug conjugate (1) in combination with the anti-PD-1 antibody, and a control group administered the dedicated solvent for antibody-drug conjugate (1). Each group contained six mice, and tumor volumes were measured until Day 43.
[0156] The results are shown in Figure 3. Tumor volume 3000 mm 3The Kaplan-Meier curve is shown when the endpoint is the time point beyond the first administration. The vertical axis shows the survival rate (%), and the horizontal axis shows the number of days from the first administration. The control group was reduced from Day 17, and all cases were euthanized by Day 24. In contrast, the antibody-drug conjugate (1) group was reduced from Day 28, and three cases survived by Day 43. The anti-PD-1 antibody group was reduced from Day 21, and two cases survived by Day 43. Furthermore, all cases survived until Day 43 in the group administered the combination of these two drugs. No weight loss was observed in any of the groups in this study. From the above, it was confirmed that the antitumor effect of single administration of both drugs was confirmed, and that the effect was dramatically enhanced by the combination of the two drugs.
[0157] [Evaluation Example 2: Life extension test] The test was carried out in the same manner as in Evaluation Example 1. The anti-PD-1 antibody was administered into the tail vein at a dose of 5 mg / kg four times in total on days 0, 3, 7 and 10, with 20 mice in each group, and tumor volumes were measured up to day 38. Comparisons of efficacy between the control group, the antibody-drug conjugate (1) group, and the anti-PD-1 antibody group, as well as between the antibody-drug conjugate (1) and anti-PD-1 antibody group and the combined use group were carried out using the Kaplan-Meier method and log-rank test (multiple group comparison). 3 The day when the number of animals exceeded the threshold (the day when the animals were euthanized) was defined as the event occurrence date (the day of death). Multiplicity-adjusted P values are reported to four decimal places, and P<0.05 (two-sided test) was considered significant. The results are shown in Figure 4. Compared to the control group, the antibody-drug conjugate (1) group showed a significantly superior antitumor effect (P = 0.0001). Also, compared to the control group, the anti-PD-1 antibody group showed a significantly superior antitumor effect (P = 0.0010). Furthermore, compared to the antibody-drug conjugate (1) group, the combination group showed a significantly superior antitumor effect (P = 0.0006). Also, compared to the anti-PD-1 antibody group, the combination group showed a significantly superior antitumor effect (P < 0.0001).
[0158] [Evaluation Example 3: Reimplantation Test] As in Evaluation Example 1, the antibody-drug conjugate (1) was administered to mice subcutaneously implanted with CT26.WT-hHER2 cells. Random grouping was performed 5 days after implantation. Among these mice, mice in which the tumor had completely disappeared were selected (hereinafter referred to as "cured mice treated with antibody-drug conjugate (1)"). In addition, untreated mice were used as controls (hereinafter referred to as "control mice"). Next, 5.0 × 10 mice were injected into the left axilla of each of the cured mice treated with antibody-drug conjugate (1) and the control mice. 6 CT26.WT-hHER2 cells or CT26.WT-mock cells were subcutaneously transplanted (re-transplantation, Day 0), and the tumor volume was measured up to Day 17. The number of mice in each group was 9. The results are shown in Figure 5. The vertical axis shows tumor volume (mm 3 ), and the horizontal axis indicates the number of days after re-implantation. When CT26.WT-hHER2 cells or CT26.WT-mock cells were re-implanted into control mice, tumor growth was observed in each case. On the other hand, when CT26.WT-hHER2 cells or CT26.WT-mock cells were re-implanted into cured mice treated with antibody-drug conjugate (1), almost no tumor growth was observed in either case, and the tumors were rejected. These results confirmed that administration of antibody-drug conjugate (1) leads to the formation of immune memory against tumors.
[0159] [Evaluation example 4: ELISPOT analysis] Murine IFNγ Single-Color Enzymatic ELISPOT Assay was used. Spleens were excised from the mice used in Evaluation Example 3, and spleen cells were incubated with CTL test medium at 1.0 x 10 6 CT26.WT-hHER2 cells and CT26.WT-mock cells were treated with 10 μg / mL mitomycin C for 2 hours, washed, and then collected and diluted at 1.0 x 10 6The antigen was prepared by adjusting the concentration of IFNγ cells / mL. Spleen cells and antigen were added to an anti-IFNγ antibody-coated PVDF-membrane plate at 100 μL / well, and co-cultured at 37°C for 24 hours, after which the number of IFNγ-producing spleen cells was measured. Comparisons between the control group and the antibody-drug conjugate (1) group were performed using Wilcoxon rank sum tests, with P values reported to four decimal places and P<0.05 (two-sided test) considered significant. The results are shown in Figures 6 to 9. The spleen cells of the cured mice treated with antibody-drug conjugate (1) and re-implanted with CT26.WT-hHER2 cells showed a significantly higher number of IFNγ-producing spleen cells when antigens derived from CT26.WT-hHER2 cells were used compared to the spleen cells of the control mice (P = 0.0012, Figure 6). In addition, the antigens derived from CT26.WT-mock cells also showed a significantly higher number of IFNγ-producing spleen cells (P = 0.0008, Figure 7). Furthermore, even when CT26.WT-mock cells were re-implanted, the spleen cells of the cured mice treated with antibody-drug conjugate (1) showed a significantly higher number of IFNγ-producing spleen cells when treated with antigen derived from CT26.WT-hHER2 cells than when treated with antigen derived from CT26.WT-mock cells (P=0.0052, FIG. 9). These results suggest that T cells that recognize antigens derived from CT26.WT cells other than human HER2 are induced in cured mice treated with antibody-drug conjugate (1).
[0160] The results of Evaluation Examples 3 and 4 demonstrated that the antibody-drug conjugate (1) has the effect of promoting immune memory formation against tumors. Moreover, this effect was observed not only against tumors expressing HER2, but also against tumors of the same origin that do not express HER2.
[0161] Therefore, it was demonstrated that the antibody-drug conjugate used in the present invention has the effect of promoting immune memory formation not only in tumors expressing an antigen against the antibody in the antibody-drug conjugate, but also in tumors within the same individual that do not express an antigen against the antibody in the antibody-drug conjugate.
[0162] [Evaluation Example 5: In vitro evaluation of effects on dendritic cells] After euthanasia of BALB / c mice, bone marrow cells were isolated from the femur and cultured for 11 days in RPMI 1640 medium containing 10% FBS, 55 μM 2-mercaptoethanol, 100 U / mL penicillin, 100 U / mL streptomycin, 1 mM sodium pyruvate, 1 × non-essential amino acid, 2 mM L-glutamine, and 10 ng / mL mouse GM-CSF to induce bone marrow-derived dendritic cells. Compound (A) was added to the culture medium of the induced dendritic cells at 0.0625 μM, 0.125 μM, 0.25 μM, 0.5 μM, and 1 μM. DMSO was also added in the same amount as compound (A) as a control. After 24 hours, the cells were stained with Pacific Blue labeled anti-mouse CD45 Antibody (103126, BioLegend), PE labeled anti-mouse CD86 (B7-2) (553692, Becton Dickinson), APC labeled anti-mouse CD11c (550261, Becton Dickinson), and FITC labeled anti-mouse MHC Class II (IA / IE) (11-5321-85, Thermo Fisher Scientific) and analyzed using a FACS Canto II. Dead cells were stained with the LIVE / DEAD Fixable Near-IR Dead Cell Stain Kit purchased from Thermo Fisher Scientific and excluded from the analysis.
[0163] The expression levels of CD86 and MHC class II in CD11c-positive cells were measured by flow cytometry, and the results are shown in Figures 10 and 11. Compared to the control DMSO, it was confirmed that the expression levels of both CD86, which is a marker for maturation and activation of dendritic cells, and MHC class II were increased by treatment with compound (A).
[0164] The results of Evaluation Example 5 demonstrated that compound (A) has the effect of activating dendritic cells.
[0165] [Evaluation Example 6: Intratumoral dendritic cell analysis] As in Evaluation Example 1, CT26.WT-hHER2 was transplanted into mice, and 8 days later, the mice were randomly divided into groups (Day 0). Antibody-drug conjugate (1) was administered intravenously into the tail vein at a dose of 10 mg / kg on Day 0. A control group was administered a solvent dedicated to antibody-drug conjugate (1). Each group had 7 mice, and on Day 8, the mice were euthanized and the tumors were removed. Single cell suspensions were prepared from the tumors using Tumor Dissociation Kit, mouse purchased from Miltenyi Biotec, and stained and analyzed in the same manner as in Evaluation Example 5. Comparisons between the control group and the antibody-drug conjugate (1) group were performed using Student's t-test, with P values reported to four decimal places and P<0.05 (two-sided test) considered significant.
[0166] The results are shown in Figures 12 to 14. It was confirmed that the number of CD11c, MHC class II, CD45 positive cells (dendritic cells, DC) among CD45 positive cells (lymphocytes) in the tumor was significantly increased by administration of the antibody-drug conjugate (1) ( FIG. 12 ). It was also confirmed that dendritic cells expressing CD86 (an activation marker) were significantly increased by administration of the antibody-drug conjugate (1) ( FIG. 13 ). Furthermore, it was confirmed that the expression level of CD86 on dendritic cells, as measured by MFI (mean fluorescence intensity), was significantly increased by administration of antibody-drug conjugate (1) (FIG. 14). These results confirmed that administration of antibody-drug conjugate (1) to tumor-bearing mice increased the number of dendritic cells among intratumoral lymphocytes, increased the number of CD86-positive cells among intratumoral dendritic cells, and increased the expression level of CD86 on dendritic cells.
[0167] The results of Evaluation Example 5 show that compound (A), which is a drug released from antibody-drug conjugate (1), itself has the effect of activating dendritic cells. The "effect of activating dendritic cells" of compound (A) is a common effect with the "effect of activating dendritic cells" of the antibody-drug conjugate used in the present invention. Compound (A) is a compound generated from the antibody-drug conjugate used in the present invention after the antibody-drug conjugate used in the present invention migrates into cancer cells. Therefore, even if the antibody portion is an antibody-drug conjugate other than an anti-HER2 antibody, it is considered to have a similar effect.
[0168] [Evaluation Example 7: Intratumoral cancer cell analysis] After preparing a cell suspension in the same manner as in Evaluation Example 6, the cells were stained with PE labeled anti-human Her2 / neu (340552, Becton Dickinson), APC labeled anti-mouse CD274 (B7-H1, PD-L1) (124312, BioLegend), and FITC labeled anti-mouse H-2Dd (110606, BioLegend), and the expression levels of MHC class I and PD-L1 on the cancer cells were measured by flow cytometry. Dead cells were stained with the LIVE / DEAD Fixable Near-IR Dead Cell Stain Kit purchased from Thermo Fisher Scientific and excluded from the analysis. Comparison between the control group and the antibody-drug conjugate (1) group was performed by Student's t-test, and the P value was reported to four decimal places, and P<0.05 (two-sided test) was considered significant.
[0169] The results are shown in Figures 15 and 16. It was confirmed that the expression level of MHC class I on cancer cells (human HER2-positive cells) was significantly increased by administration of antibody-drug conjugate (1) (Figure 15). MHC class I is a molecule required for T cells to recognize cancer cells. Therefore, it was suggested that antibody-drug conjugate (1) activates anti-tumor immunity by promoting the increase in the expression level of MHC class I on cancer cells. It was also confirmed that the expression level of PD-L1 on cancer cells was significantly increased by antibody-drug conjugate (1) (Figure 16). PD-L1 is known to act on PD-1 on T cells to transmit immunosuppressive signals. Therefore, it is suggested that antibody-drug conjugate (1) suppresses anti-tumor immunity by promoting an increase in the expression level of PD-L1 on cancer cells, and it is believed that the inhibitory signal is released by combining it with a PD-1 antibody, resulting in a stronger anti-tumor effect.
[0170] [Evaluation example 8: in vitro cancer cell analysis] Compound (A) was added to the culture medium of CT26.WT-hHER2 cells at 0.0625 μM, 0.125 μM, 0.25 μM, 0.5 μM, and 1 μM. As a control, DMSO was added in the same amount as compound (A). After 24 hours, the cells were stained with PE labeled anti-human Her2 / neu (340552, Becton Dickinson) and FITC labeled anti-mouse H-2Dd (110606, BioLegend), and the expression level of MHC class I on the cancer cells was measured by flow cytometry. Dead cells were stained with LIVE / DEAD Fixable Near-IR Dead Cell Stain Kit purchased from Thermo Fisher Scientific and excluded from the analysis. The mean fluorescence intensity (MFI) of MHC class I was calculated, and the adjusted MFI was calculated by subtracting the MFI of the cells treated with isotype control from the MFI of the stained cells. Comparison between the control group and the compound (A) group was performed by Dunnett's test, and P values were reported to four decimal places, with P<0.05 (two-sided test) considered significant. The results are shown in Figure 17. It was confirmed that the expression level of MHC class I on CT26.WT-hHER2 cells was significantly increased by compound (A) (Figure 17). Therefore, it was suggested that compound (A) activates antitumor immunity by promoting the increase in the expression level of MHC class I on cancer cells.
[0171] [Evaluation Example 9: Antitumor test using nude mice] Mice: Six-week-old female BALB / c-nu mice (CAnN.Cg-Foxn1[nu] / CrlCrlj〔Foxn1nu / Foxn1nu〕) (Charles River Biosciences Japan) were used in the experiment. Measurement and calculation formula: The long and short diameters of the tumor were measured twice a week using an electronic digital caliper (CD15-CX, Mitutoyo Corporation), and the tumor volume (mm 3 ) was calculated using the following formula: Tumor volume (mm 3 ) = 0.5 x major axis (mm) x [minor axis (mm)] 2 Tumor volume 3000 mm 3 Any individuals exceeding this limit were euthanized from the standpoint of animal experiment ethics.
[0172] The antibody-drug conjugate (1) was administered into the tail vein at a dose of 10 mL / kg. CT26.WT-hHER2 cells were suspended in saline at 5.0 × 10 6 The cells were subcutaneously transplanted into the right axilla of BALB / c-nu mice, and three days later, the mice were randomly divided into groups (Day 0). Antibody-drug conjugate (1) was administered twice in total into the tail vein at a dose of 10 mg / kg on Days 0 and 7. A control group was administered the solvent for antibody-drug conjugate (1). Each group contained 12 mice, and tumor volumes were measured up to Day 13.
[0173] The results are shown in Figure 18. The vertical axis represents tumor volume (mm 3 ), and the horizontal axis indicates the number of days from the first administration. The antitumor effect of antibody-drug conjugate (1) administration observed in BALB / c mice was not observed in BALB / c-nu mice. Since the numbers of T cells and B cells in BALB / c-nu mice are reduced and their functions are impaired, it is believed that these cells play an important role in the antitumor effect of antibody-drug conjugate (1).
[0174] [Evaluation Example 10: Antitumor Test] For the antibody-drug conjugate (1) administration group, the control antibody-drug conjugate administration group, and the control group, the time course of tumor volume was measured in mice subcutaneously implanted with CT26.WT-hHER2 cells in the same manner as in Evaluation Example 1. A control antibody-drug conjugate (Drug-to-Antibody Ratio: 7.8) using a human IgG1 antibody that binds to molecules other than those derived from mouse or human was used after dilution with a dedicated solvent. Grouping was performed 5 days after transplantation (Day 0). The control antibody-drug conjugate and antibody-drug conjugate (1) were administered into the tail vein at a dose of 10 mg / kg twice in total on Days 0 and 7. There were 10 mice in each group, and tumor volumes were measured up to Day 10. The efficacy of the control antibody-drug conjugate group and the antibody-drug conjugate (1) group were compared using the Wilcoxon rank sum test. P values are reported to four decimal places, and P<0.05 (two-sided test) was considered significant.
[0175] The results are shown in Figure 19. The vertical axis shows tumor volume (mm 3 ), and the horizontal axis indicates the number of days from the first administration. At day 10, the antibody-drug conjugate (1) group showed a significantly superior antitumor effect compared to the control antibody-drug conjugate group (P = 0.0003). From the above, it was confirmed that the antitumor effect of antibody-drug conjugate (1) is target-dependent.
[0176] [Evaluation Example 11: Antitumor Test] The change in tumor volume in mice subcutaneously implanted with EMT6-hHER2 cells was measured for the antibody-drug conjugate (1) and anti-PD-1 antibody (clone RMP1-14) monotherapy and combination therapy groups in the same manner as in Evaluation Example 1. The EMT6-hHER2 cells were generated by introducing the human HER2 gene into the mouse breast cancer cell line EMT6 (CRL-2755) purchased from American Type Culture Collection using a lentivirus vector. These cells express human HER2 protein on the cell membrane. The EMT6-hHER2 cells were suspended in saline and 1.0 × 10 6The cells were subcutaneously transplanted into the right axilla of 5-week-old BALB / c mice, and 4 days after transplantation, the mice were randomly divided into groups (Day 0). Antibody-drug conjugate (1) was administered once into the tail vein at a dose of 10 mg / kg on Day 0. Anti-PD-1 antibody (clone RMP1-14) was prepared in D-PBS(-) (WAKO) and administered into the tail vein at a dose of 5.0 mg / kg four times in total on Days 0, 3, 7, and 10. In addition, a group was administered the antibody-drug conjugate (1) in combination with the anti-PD-1 antibody, and a control group was administered the dedicated solvent for antibody-drug conjugate (1). Each group contained 11 mice, and tumor volumes were measured until Day 17. Comparisons of efficacy between the control group, the antibody-drug conjugate (1) group, and the anti-PD-1 antibody group, and comparisons of efficacy between the antibody-drug conjugate (1) and anti-PD-1 antibody groups and the combined use group were performed using Dunnett's test (multiple group comparisons). Multiplicity-adjusted P values are reported to four decimal places, and P<0.05 (two-sided test) was considered significant.
[0177] The results are shown in Figure 20. The vertical axis shows tumor volume (mm 3 ), and the horizontal axis indicates the number of days from the first administration. At day 17, the antibody-drug conjugate (1) group showed a significantly superior antitumor effect compared to the control group (P<0.0001). In addition, the anti-PD-1 antibody group showed a significantly superior antitumor effect compared to the control group (P<0.0001). Furthermore, the combination group showed a significantly superior antitumor effect compared to the antibody-drug conjugate (1) group (P=0.0136). In addition, the combination group showed a significantly superior antitumor effect compared to the anti-PD-1 antibody group (P=0.0372). Furthermore, no weight loss was observed in mice in any of the groups in this study. From the above, it was confirmed that the antitumor effect of single administration of both drugs was confirmed, and that the effect was dramatically enhanced by the combination of the two drugs.
[0178] [Evaluation Example 12: Life extension test] The survival benefit of mice subcutaneously transplanted with CT26.WT-hHER2 cells was measured for the antibody-drug conjugate (1) and anti-PD-L1 antibody single agent and combination group in the same manner as in Evaluation Example 1. Anti-PD-L1 antibody (clone 10F.9G2) was purchased from Bio X Cell and diluted with InVivoPure pH6.5 Dilution Buffer (Bio X Cell). Six days after transplantation, the mice were randomly divided into groups (Day 0), and antibody-drug conjugate (1) was administered into the tail vein at a dose of 10 mg / kg twice on Days 0 and 7. Anti-PD-L1 antibody was administered into the tail vein at a dose of 5 mg / kg twice on Days 0 and 3. In addition, a group administered the antibody-drug conjugate (1) and anti-PD-L1 antibody in combination and a control group administered the dedicated solvent for antibody-drug conjugate (1) were set up. The number of mice in each group was 15, and tumor volumes were measured up to Day 38. 3 The day when the number of patients exceeded the threshold (the day of euthanasia) was defined as the event occurrence date (the day of death), and the survival times of the control group, the antibody-drug conjugate (1) group, and the anti-PD-L1 antibody group, as well as the antibody-drug conjugate (1) group, the anti-PD-L1 antibody group, and the combination group were compared using the Kaplan-Meier method and log-rank test (multiple group comparison). Multiplicity-adjusted P values are reported to four decimal places, and P<0.05 (two-sided test) was considered significant.
[0179] The results are shown in Figure 21. Compared to the control group, the antibody-drug conjugate (1) group showed a significantly superior antitumor effect (P = 0.0069). Also, compared to the control group, the anti-PD-L1 antibody group showed a significantly superior antitumor effect (P = 0.0037). Furthermore, compared to the antibody-drug conjugate (1) group, the combination group showed a significantly superior antitumor effect (P = 0.0059). Also, compared to the anti-PD-L1 antibody group, the combination group showed a significantly superior antitumor effect (P = 0.0091). Furthermore, no weight loss was observed in mice in any of the groups in this study. From the above, it was confirmed that the antitumor effect of single agent administration of both drugs was confirmed, and that the effect was enhanced by the combination of the two drugs.
[0180] [Evaluation Example 13: Life extension test] EMT6-hHER2 cells were subcutaneously transplanted into mice in the same manner as in Evaluation Example 11, and the survival benefit was measured for the antibody-drug conjugate (1) and anti-PD-L1 antibody monotherapy group and combination group in the same manner as in Evaluation Example 12. Five days after transplantation, the mice were randomly divided into groups (Day 0), and the antibody-drug conjugate (1) was administered once into the tail vein on Day 0 at a dose of 10 mg / kg. The anti-PD-L1 antibody was administered twice in total into the tail vein on Days 0 and 3 at a dose of 5 mg / kg. In addition, a combination group of the antibody-drug conjugate (1) and the anti-PD-L1 antibody and a control group administered the dedicated solvent for the antibody-drug conjugate (1) were set. The number of mice in each group was 6, and the tumor volume was measured until Day 60. Comparisons of survival times between the control group, the antibody-drug conjugate (1) group, and the anti-PD-L1 antibody group, as well as between the antibody-drug conjugate (1) group, the anti-PD-L1 antibody group, and the combination group were performed using the Kaplan-Meier log-rank test (multiple group comparison). Multiplicity-adjusted P values are reported to four decimal places, and P<0.05 (two-sided test) was considered significant.
[0181] The results are shown in Figure 22. Compared to the control group, the antibody-drug conjugate (1) group showed a significantly superior antitumor effect (P = 0.0006). Also, compared to the control group, the anti-PD-L1 antibody group showed a significantly superior antitumor effect (P = 0.0227). Furthermore, compared to the antibody-drug conjugate (1) group, the combination group showed a significantly superior antitumor effect (P = 0.0039). Furthermore, no weight loss was observed in mice in any of the groups in this study. From the above, it was confirmed that the antitumor effect of single agent administration of both drugs was confirmed, and that the effect was enhanced by the combination of the two drugs.
[0182] [Evaluation Example 14: In vivo CD4 / 8 depletion test] The transition of tumor volume in mice subcutaneously implanted with CT26.WT-hHER2 cells was measured for the antibody-drug conjugate (1) and anti-CD4 antibody single agent and combined use groups, and for the antibody-drug conjugate (1) and anti-CD8 antibody single agent and combined use groups, in the same manner as in Evaluation Example 1. Antibody-drug conjugate (1) was administered at 10 mg / kg, and depletion antibodies anti-CD4 antibody (Bio X Cell, clone GK1.5) and anti-CD8 antibody (Bio X Cell, clone 53.6.7) were prepared at 1 mg / mL using D-PBS(-) immediately before administration, and administered to mice at 200 μg / head into the tail vein on days 0 and 7. A control group was also administered with the dedicated solvent for antibody-drug conjugate (1). Grouping was performed on the 5th day (Day 0) after implantation, and tumor volume was measured until Day 11.
[0183] The results are shown in Figures 23 and 24. The tumor volume in the antibody-drug conjugate (1) group on Day 11 was 651 mm 3 , and the antibody-drug conjugate (1) and anti-CD4 antibody combination group had a mean score of 561 mm 3 This suggests that CD4-positive cells do not contribute to the antitumor effect of antibody-drug conjugate (1) (FIG. 23). The tumor volume in the antibody-drug conjugate (1) group on Day 11 was 651 mm 3 , and the antibody-drug conjugate (1) and anti-CD8 antibody combination group had a mean score of 2247 mm 3 This suggests that CD8-positive cells contribute to the antitumor effect of the antibody-drug conjugate (1) (Figure 24). In addition, in the anti-CD4 antibody group and the anti-CD8 antibody group, some individuals had a tumor volume of 3,000 mm 3 The tumor growth curve was interrupted at the time of euthanasia. In the tumor model using immunodeficient nude mice in Evaluation Example 9, it was shown that T cells or B cells are involved in part of the efficacy of antibody-drug conjugate (1), and furthermore, based on the results of this study, it was suggested that CD8 positive T cells contribute to the antitumor effect of antibody-drug conjugate (1).
[0184] [Evaluation Example 15: Intratumoral T cell analysis] When antibody-drug conjugate (1) was administered to mice subcutaneously implanted with CT26.WT-hHER2 cells, the percentage of CD8 positive T cells among live cells in the tumor, the percentage of Granzyme B positive cells among live CD8 positive T cells in the tumor, the percentage of Granzyme B positive CD8 positive T cells among live cells in the tumor, and the percentage of CD4 positive T cells among live cells in the tumor were measured by flow cytometry. A cell suspension was prepared in the same manner as in Evaluation Example 6, and then stained with Pacific Blue labeled anti-mouse CD45 antibody (103126, BioLegend), PE labeled anti-mouse CD3e antibody (553064, Becton Dickinson), PerCP / Cy5.5 labeled anti-mouse CD4 antibody (100434, BioLegend), PE-Cy 7 labeled anti-mouse CD8a antibody (552877, Becton Dickinson), and Alexa FluorR 647 labeled anti-human / mouse Granzyme B antibody (515405, BioLegend), and measured by flow cytometry. Dead cells were stained with the LIVE / DEAD Fixable Near-IR Dead Cell Stain Kit purchased from Thermo Fisher Scientific and excluded from the analysis. Comparison between the control group and the antibody-drug conjugate (1) group was performed using Student's t-test. P values are reported to four decimal places, and P<0.05 (two-sided test) was considered significant.
[0185] The results are shown in Figures 25 to 28. It was confirmed that the proportion of CD45, CD3, and CD8 positive cells (CD8 positive T cells) among live cells was significantly increased by administration of antibody-drug conjugate (1) (Figure 25). It was confirmed that the proportion of Granzyme B positive cells among CD8 positive T cells was significantly increased by administration of antibody-drug conjugate (1) (Figure 26). It was confirmed that the proportion of Granzyme B positive CD8 positive T cells among live cells was significantly increased by administration of antibody-drug conjugate (1) (Figure 27). The proportion of CD45, CD3, and CD4 positive cells (CD4 positive T cells) among live cells tended to increase by administration of antibody-drug conjugate (1), but the difference was not significant (Figure 28). Therefore, it was suggested that the antibody-drug conjugate (1) increased intratumor CD8 positive T cells and promoted their activation, thereby activating antitumor immunity.
[0186] [Evaluation example 16: CD8 IHC analysis] The number of CD8 positive cells per unit area in the tumor was measured by IHC when antibody-drug conjugate (1) was administered to mice subcutaneously implanted with CT26.WT-hHER2 cells. Control and antibody-drug conjugate (1) were administered in the same manner as in Evaluation Example 6, and the mice were euthanized 8 days after administration. The number of mice in each group was 5, and tumors from 3 mice (the median number) were excised and infiltrated with 4% paraformaldehyde-phosphate buffer to prepare paraffin blocks. The tumors were stained with anti-CD8 antibody (clone: 4SM16), and specimen images were captured using NanoZoomer 2.0-HT (Hamamatsu Photonics), and analysis was performed on the entire tissue area using the image analysis software Tissue Studio 3.0 (Definiens).
[0187] The results are shown in Figures 29 and 30. It was confirmed that the antibody-drug conjugate (1) tended to increase the number of CD8 positive cells per unit area in the tumor. [Evaluation Example 17: In vitro cancer cell analysis] The expression level of MHC class I was measured when cancer cells were treated with various compounds. In the same manner as in Evaluation Example 8, compound (A), DM1-SMe, DM4-SMe (J. Med. Chem. (2014), 57, 16, 6949-6964) and MMAE (Molecular Cancer Therapeutics (2011), 10, 9, 1728-1739) were added at 20 nM, 100 nM and 500 nM, and the expression level of MHC class I on cancer cells was measured by flow cytometry. The experiment was performed in triplicate. Comparison between the control group and each concentration of drug group was performed by Dunnett's test, and P values are listed to four decimal places, and P<0.05 (two-sided test) was considered significant (***: P<0.001, **: P<0.01).
[0188] The results are shown in Figure 31. It was confirmed that all of the drugs evaluated at the concentrations examined (20 nM, 100 nM, 500 nM) significantly increased MHC class I expression on CT26.WT-hHER2 cells compared to the control group. Among them, it was confirmed that compound (A) showed the greatest effect of increasing MHC class I expression on CT26.WT-hHER2 cells.
[0189] [Evaluation Example 18: Antitumor Test] The transition of tumor volume in mice subcutaneously implanted with EMT6-hHER2 cells was measured for the antibody-drug conjugate (1) and anti-CTLA-4 antibody single agent administration group and combined administration group in the same manner as in Evaluation Example 11. Anti-CTLA-4 antibody (clone 9H10) was purchased from Bio X Cell and used after dilution with D-PBS(-). The mice were divided into groups on the 5th day after implantation (Day 0). Antibody-drug conjugate (1) was administered once into the tail vein at a dose of 10 mg / kg on Day 0. Anti-CTLA-4 antibody was administered three times in total on Days 0, 3, and 7 at a dose of 5.0 mg / kg on Days 0, 3, and 7. In addition, a combined antibody-drug conjugate (1) and anti-CTLA-4 antibody administration group and a control group administered with the dedicated solvent for antibody-drug conjugate (1) were set. The number of mice in each group was 10, and the tumor volume was measured until Day 14. Comparisons of efficacy between the control group, the antibody-drug conjugate (1) group, and the anti-CTLA-4 antibody group, and comparisons of efficacy between the antibody-drug conjugate (1) and anti-CTLA-4 antibody groups and the combined use group were performed using Dunnett's test (multiple group comparisons). Multiplicity-adjusted P values are reported to four decimal places, and P<0.05 (two-sided test) was considered significant.
[0190] The results are shown in Figure 32. The vertical axis shows tumor volume (mm 3 ), and the horizontal axis indicates the number of days from the first administration. At day 14, the antibody-drug conjugate (1) group showed a significantly superior antitumor effect compared to the control group (P = 0.0011). Furthermore, the anti-CTLA-4 antibody group showed a significantly superior antitumor effect compared to the control group (P = 0.0006). Furthermore, the combination group showed a significantly superior antitumor effect compared to the antibody-drug conjugate (1) group (P = 0.0115). Furthermore, the combination group showed a significantly superior antitumor effect compared to the anti-CTLA-4 antibody group (P = 0.0309). From the above, it was confirmed that the antitumor effect of the single administration of both drugs was confirmed, and that the effect was dramatically enhanced by the combination of the two drugs.
[0191] From the above experimental results, it was found that the antibody-drug conjugate according to the present invention exhibits a dramatically superior antitumor effect when administered in combination with an immune checkpoint inhibitor. In addition, it was shown that the antibody-drug conjugate according to the present invention has the effect of activating antitumor immunity. This makes it possible to provide a pharmaceutical composition and a treatment method that are excellent in antitumor effect and safety. [Sequence List Free Text]
[0192] SEQ ID NO: 1: Amino acid sequence of the humanized anti-HER2 antibody heavy chain SEQ ID NO:2: Amino acid sequence of the humanized anti-HER2 antibody light chain
Claims
1. A pharmaceutical composition comprising an antibody-drug conjugate and an immune checkpoint inhibitor administered in combination, The antibody-drug conjugate has the formula [Formula 1] (wherein A represents the binding site to the antibody) and an antibody via a thioether bond.
2. The pharmaceutical composition according to claim 1, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody.
3. The pharmaceutical composition according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
4. The pharmaceutical composition according to claim 2 or 3, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO:
2.
5. The pharmaceutical composition according to claim 2 or 3, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:
2.
6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 2 to 8.
7. The pharmaceutical composition according to any one of claims 1 to 5, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.
8. The pharmaceutical composition according to any one of claims 1 to 5, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7.5 to 8.
9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.
10. The pharmaceutical composition of claim 9 , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.
11. The pharmaceutical composition of claim 9 , wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody.
12. The pharmaceutical composition of claim 9 , wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody.
13. The pharmaceutical composition according to any one of claims 1 to 12, wherein the antibody-drug conjugate and the immune checkpoint inhibitor are contained as active ingredients in different formulations and are administered simultaneously or at different times.
14. The pharmaceutical composition according to any one of claims 1 to 12, wherein the antibody-drug conjugate and the immune checkpoint inhibitor are contained as active ingredients in a single formulation and administered.
15. A pharmaceutical composition according to any one of claims 1 to 14 for the treatment of cancer.
16. The pharmaceutical composition according to claim 15, wherein the cancer is at least one selected from the group consisting of lung cancer, urothelial carcinoma, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
17. The pharmaceutical composition of claim 16, wherein the cancer is colon cancer.
18. The pharmaceutical composition of claim 16, wherein the cancer is breast cancer.
19. The pharmaceutical composition according to any one of claims 1 to 18, wherein the antibody-drug conjugate has an effect of activating anti-tumor immunity.
20. The antibody-drug conjugate is (1) The effect of promoting the increase of intratumoral CD8 positive T cells, and (2) Activation of intratumoral CD8-positive T cells The pharmaceutical composition according to any one of claims 1 to 19, having at least one effect selected from the group consisting of:
21. The pharmaceutical composition according to any one of claims 1 to 20, wherein the antibody-drug conjugate has an effect of promoting immune memory formation against a tumor.
22. The pharmaceutical composition of claim 21, wherein the tumor expresses an antigen against which the antibody in the antibody-drug conjugate is directed.
23. The pharmaceutical composition of claim 21, wherein the portion of the tumor does not express an antigen against which the antibody in the antibody-drug conjugate is directed.
24. The antibody-drug conjugate is (1) The effect of promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; The pharmaceutical composition according to any one of claims 1 to 23, having at least one effect selected from the group consisting of:
25. The pharmaceutical composition according to any one of claims 1 to 24, wherein the antibody-drug conjugate exhibits a stronger antitumor effect by releasing an immunosuppressive signal generated by promoting an increase in the expression level of PD-L1 on cancer cells with the immune checkpoint inhibitor.
26. formula [Case 2] (wherein A represents the binding site to the antibody) and an antibody via a thioether bond, and the pharmaceutical composition is used for treating a disease that is improved by the activity of activating anti-tumor immunity.
27. The antibody-drug conjugate is (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells The pharmaceutical composition according to claim 26, having at least one effect selected from the group consisting of:
28. The pharmaceutical composition according to claim 26 or 27, wherein the antibody-drug conjugate has the effect of promoting immune memory formation against a tumor.
29. The pharmaceutical composition of claim 28, wherein the tumor expresses an antigen against which the antibody in the antibody-drug conjugate is directed.
30. The pharmaceutical composition of claim 28, wherein the portion of the tumor does not express an antigen against which the antibody in the antibody-drug conjugate is directed.
31. The antibody-drug conjugate is (1) The effect of promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; The pharmaceutical composition according to any one of claims 26 to 30, having at least one effect selected from the group consisting of:
32. The pharmaceutical composition according to any one of claims 26 to 31, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody.
33. The pharmaceutical composition of claim 32, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
34. The pharmaceutical composition according to claim 32 or 33, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO:
2.
35. The pharmaceutical composition according to claim 32 or 33, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:
2.
36. The pharmaceutical composition according to any one of claims 26 to 35, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 2 to 8.
37. The pharmaceutical composition according to any one of claims 26 to 35, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.
38. The pharmaceutical composition according to any one of claims 26 to 35, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7.5 to 8.
39. The pharmaceutical composition according to any one of claims 26 to 38, wherein the disease is at least one selected from the group consisting of lung cancer, urothelial cancer, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
40. 40. The pharmaceutical composition of claim 39, wherein the disease is colon cancer.
41. 40. The pharmaceutical composition of claim 39, wherein the disease is breast cancer.
42. formula [C3] A pharmaceutical composition for use in the treatment of a disease that is improved by the activity of activating anti-tumor immunity, comprising a compound represented by the formula (I):
43. The compound is (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells The pharmaceutical composition according to claim 42, having at least one effect selected from the group consisting of:
44. The pharmaceutical composition according to claim 42 or 43, wherein the compound has the effect of promoting immune memory formation against a tumor.
45. The compound is (1) The effect of promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; The pharmaceutical composition according to any one of claims 42 to 44, having at least one effect selected from the group consisting of:
46. The pharmaceutical composition according to any one of claims 42 to 45, wherein the disease is at least one selected from the group consisting of lung cancer, urothelial cancer, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
47. A therapeutic method comprising administering an antibody-drug conjugate and an immune checkpoint inhibitor in combination, The antibody-drug conjugate has the formula [C4] (wherein A represents the binding site to the antibody) and an antibody-drug conjugate in which the drug linker represented by the formula:
48. The method of treatment according to claim 47, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody.
49. The method of treatment according to claim 48, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
50. The therapeutic method according to claim 48 or 49, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO:
2.
51. The method of treatment according to claim 48 or 49, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:
2.
52. The method of any one of claims 47 to 51, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 2 to 8.
53. The method of any one of claims 47 to 51, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.
54. The method of any one of claims 47 to 51, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7.5 to 8.
55. 55. The method of treatment of any one of claims 47 to 54, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.
56. The method of treatment of claim 55, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.
57. 56. The method of claim 55, wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody.
58. The method of treatment of claim 55, wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody.
59. The method of treatment according to any one of claims 47 to 58, wherein the antibody-drug conjugate and the immune checkpoint inhibitor are contained as active ingredients in different formulations and are administered simultaneously or at different times.
60. The method of treatment according to any one of claims 47 to 58, wherein the antibody-drug conjugate and the immune checkpoint inhibitor are contained as active ingredients in a single formulation and administered.
61. 61. A method of treatment according to any one of claims 47 to 60 for the treatment of cancer.
62. The method of claim 61, wherein the cancer is at least one selected from the group consisting of lung cancer, urothelial carcinoma, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
63. The method of claim 62, wherein the cancer is colon cancer.
64. 63. The method of claim 62, wherein the cancer is breast cancer.
65. The method of treatment according to any one of claims 47 to 64, wherein the antibody-drug conjugate has the effect of activating anti-tumor immunity.
66. The antibody-drug conjugate is (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells 66. The method of claim 47, having at least one effect selected from the group consisting of:
67. The therapeutic method according to any one of claims 47 to 66, wherein the antibody-drug conjugate has the effect of promoting immune memory formation against a tumor.
68. The method of claim 67, wherein the tumor expresses an antigen against which the antibody in the antibody-drug conjugate is directed.
69. The method of claim 67, wherein the portion of the tumor does not express an antigen against which the antibody in the antibody-drug conjugate is directed.
70. The antibody-drug conjugate is (1) The effect of promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; 70. The method of claim 47, having at least one effect selected from the group consisting of:
71. The therapeutic method according to any one of claims 47 to 70, wherein the antibody-drug conjugate exhibits a stronger antitumor effect by releasing an immunosuppressive signal generated by promoting an increase in the expression level of PD-L1 on cancer cells using an immune checkpoint inhibitor.
72. formula [C5] (wherein A represents the binding site to the antibody) and an antibody via a thioether bond, wherein the antibody-drug conjugate is administered to the subject.
73. The antibody-drug conjugate is (1) Promoting the increase of intratumoral CD8 positive T cells; and (2) Activation of intratumoral CD8-positive T cells The method of claim 72, having at least one effect selected from the group consisting of:
74. The therapeutic method according to claim 72 or 73, wherein the antibody-drug conjugate has the effect of promoting immune memory formation against a tumor.
75. The method of treatment of claim 74, wherein the tumor expresses an antigen against which the antibody in the antibody-drug conjugate is directed.
76. The method of claim 74, wherein the portion of the tumor does not express an antigen against which the antibody in the antibody-drug conjugate is directed.
77. The antibody-drug conjugate is (1) The effect of promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; 77. The method of claim 72, having at least one effect selected from the group consisting of:
78. The method of treatment according to any one of claims 72 to 77, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody.
79. The method of treatment of claim 78, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
80. The therapeutic method described in claim 78 or 79, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO:
2.
81. The therapeutic method according to claim 78 or 79, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:
2.
82. The method of any one of claims 72 to 81, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 2 to 8.
83. The method of any one of claims 72 to 81, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.
84. The method of any one of claims 72 to 81, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7.5 to 8.
85. The method of any one of claims 72 to 84, wherein the disease is at least one selected from the group consisting of lung cancer, urothelial carcinoma, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
86. 86. The method of claim 85, wherein the disease is colon cancer.
87. 86. The method of claim 85, wherein the disease is breast cancer.
88. formula [C6] A method for treating a disease which can be improved by the action of releasing a compound represented by the formula (I) into a tumor and activating antitumor immunity.
89. The compound is (1) The effect of promoting the increase of intratumoral CD8 positive T cells, and (2) Activation of intratumoral CD8-positive T cells The method of claim 88, having at least one effect selected from the group consisting of:
90. The therapeutic method of claim 88 or 89, wherein the compound has the effect of promoting immune memory formation against a tumor.
91. The compound is (1) The effect of promoting an increase in the number of dendritic cells in tumors; (2) Activation of dendritic cells; and (3) Promoting an increase in the expression of MHC class I on cancer cells; The method of any one of claims 88 to 90, having at least one effect selected from the group consisting of:
92. The method of any one of claims 88 to 91, wherein the disease is at least one selected from the group consisting of lung cancer, urothelial carcinoma, colon cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
Citation Information
Patent Citations
Human CTLA-4 antibodies and their uses
WO2001014424A2
Anti-PD-l1 antibodies and their use to enhance t-cell function
WO2010077634A1
Human monoclonal antibodies to CTLA-4
WO2000037504A2
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using Anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2006121168A1
Antibodies to human programmed death receptor PD-1
WO2008156712A1
